It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).

Skip Navigation

News & Media

Explore our press releases, fact sheets, and other resources to find the latest news and information about Baxter. Also, follow us on our corporate social media channels.

Filter by:

Jul 29, 2015

DEERFIELD, Ill., July 29, 2015 – Baxter International Inc. (NYSE:BAX) today declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.... Read More

Jul 29, 2015

DEERFIELD, Ill., July 29, 2015 – Baxter International Inc. (NYSE:BAX) today reported second quarter financial results that exceeded the company’s previously issued guidance, and provided its complete financial outlook for the second half of 2015. The results for the second quarter of 2015 include the company’s BioScience business, which was officially spun-off on July 1st and is now operating as a publicly traded biopharmaceutical company, Baxalta Incorporated (NYSE: BXLT). Starting in the third quarter of 2015, the BioScience business will be presented as a discontinued operation in Baxter’s results.... Read More

Jul 17, 2015

DEERFIELD, Ill., July 17, 2015 – Baxter International Inc. announced today it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to patient administration and there have been no adverse events associated with this issue reported to Baxter.... Read More

Jul 8, 2015

DEERFIELD, Ill., July 08, 2015 - Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its second quarter 2015 financial results on Wednesday, July 29, 2015, at 4:00 p.m. Central Time.... Read More

Jul 2, 2015

DEERFIELD – July 2, 2015 – Baxter International Inc. (NYSE: BAX) announced today the preliminary results, as of 5:00 p.m. New York City (“NYC”) time on July 1, 2015 (the “Early Tender Time”), of its previously announced cash tender offers (the “Tender Offers”) for specified series of its outstanding debt. As of the Early Tender Time, the aggregate principal amount of notes listed in the table below validly tendered and not validly withdrawn pursuant to the Any and All Tender Offer (as defined in Baxter’s Offer to Purchase dated June 18, 2015, the “Offer to Purchase”) was approximately $1.1 billion and the aggregate principal amount of notes validly tendered and not validly withdrawn pursuant to the Maximum Tender Offer (as defined in the Offer to Purchase) was approximately $1.6 billion. The table below sets forth the approximate aggregate principal amount of each series of notes that was validly tendered and not validly withdrawn at or prior to the Early Tender Time, as reported by D.F. King & Co., Inc, the Tender Agent.... Read More

Jul 1, 2015

DEERFIELD – July 1, 2015 – Baxter International Inc. (NYSE: BAX) announced today the determination of the Total Consideration (as defined in Baxter’s Offer to Purchase dated June 18, 2015, the “Offer to Purchase”) for all series of notes listed in the table below in connection with Baxter’s previously announced cash tender offers (the “Tender Offers”) for specified series of its outstanding debt. The Total Consideration for the 3.650% Notes due August 2042 (the “2042 Notes”) was fixed at the commencement of the Tender Offers.... Read More

Jun 24, 2015

Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE:BAX), today reported continued progress on the Phase 1/2 open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B, during an oral presentation at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress in Toronto, Canada.... Read More

Jun 19, 2015

DEERFIELD, Ill., June 19, 2015 -- Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE: BAX), announced today that it has priced a private placement offering of $375,000,000 of 2.000% senior notes due 2018 (the "2018 Notes"), $1,000,000,000 of 2.875% senior notes due 2020 (the "2020 Notes"), $500,000,000 of 3.600% senior notes due 2022 (the "2022 Notes"), $1,750,000,000 of 4.000% senior notes due 2025 (the "2025 Notes"), $1,000,000,000 of 5.250% senior notes due 2045 (the "2045 Notes"), and $375,000,000 of floating rate senior notes due 2018 (the "Floating Rate Notes," and, together with the 2018 Notes, the 2020 Notes, the 2022 Notes, the 2025 Notes and the 2045 Notes, the "Notes"). The closing of the offering is expected to occur on June 23, 2015, subject to customary closing conditions. Interest on the 2020 Notes, the 2022 Notes, the 2025 Notes and the 2045 Notes will be payable semi-annually on June 23 and December 23 of each year, beginning on December 23, 2015.... Read More

Jun 19, 2015

Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE:BAX), will highlight the breadth and depth of its hematology portfolio and commitment to innovation in hemophilia and blood disorders with the presentation of new data at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress taking place June 20-25 in Toronto, Canada. Researchers and investigators will discuss the safety and effectiveness of the company's leading brands ADVATE and FEIBA, and will showcase strong clinical data supporting investigational products, including BAX 855 intended for the treatment of hemophilia A, BAX 111 for von Willebrand disease, and potential new treatments for other coagulation disorders.... Read More

Jun 18, 2015

Baxter International Inc. (NYSE: BAX) announced today that it has commenced two cash tender offers for specified series of its outstanding debt.... Read More

Jun 10, 2015

Baxter International Inc. (NYSE: BAX) today issued its 16th annual Sustainability Report detailing the company's progress creating social, environmental and economic value by addressing the needs of stakeholders worldwide.... Read More

Jun 9, 2015

DEERFIELD, Ill., June 9, 2015 - Baxter International Inc. (NYSE:BAX), announced today that the Registration Statement on Form 10 filed by Baxalta Incorporated has been declared effective by the Securities and Exchange Commission (SEC) (available at www.baxter.com/transition). The Registration Statem... Read More

Jun 5, 2015

Baxter International Inc. (NYSE:BAX), announced today that its board of directors has approved the planned separation of its biopharmaceuticals business, which will be known as Baxalta Incorporated, and declared a special dividend distribution of 80.5 percent of the outstanding shares of Baxalta common stock. Baxter will retain a 19.5 percent ownership stake in Baxalta immediately following the distribution.... Read More

Jun 1, 2015

Baxter Ventures, the venture arm of Baxter International Inc. (NYSE:BAX), the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced the formation of Vitesse Biologics, LLC, ("Vitesse"). Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology. Following the spin-off of Baxter BioScience as Baxalta Incorporated, anticipated to take place by mid-2015, the Vitesse relationship will be managed by the planned venture arm, Baxalta Ventures, for the new company.... Read More

Jun 1, 2015

Baxter International Inc. announced today it is voluntarily recalling four product codes of its VASCU-GUARD Peripheral Vascular Patch. Baxter received customer complaints of difficulty in distinguishing the smooth from rough surface of the VASCU-GUARD patch as described in the labeled instructions for use. This is due to a deviation in the surface texture of the vascular patch in a new packaging configuration. Incorrect orientation of the patch with the rough side toward the bloodstream may increase the risk of vessel thrombosis and/or embolism.... Read More

May 29, 2015

Baxter International Inc. (NYSE:BAX) today presented data showing how innovative dialysis systems with new remote connectivity may improve patient access to home therapy. The data, presented at the 52nd Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), includes the perceptions of more than 500 healthcare providers and patients regarding the benefits associated with advanced automated peritoneal dialysis (APD) cyclers with remote monitoring capabilities of home patients (Abstract # FP586), and several abstracts supporting cost-effectiveness and utility of High Dose Hemodialysis (HD).... Read More

May 28, 2015

Executives from Baxter International Inc. (NYSE: BAX) and Baxalta Incorporated will present at the Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, 2015. Baxalta will present at 12:40 p.m. (CDT) and Baxter will present at 3:20 p.m. (CDT).... Read More

May 18, 2015

As separate, independent companies, both Baxter and Baxalta will remain leaders in their respective markets, each with an established global presence. The businesses operate in distinct markets, and each possesses unique and compelling growth prospects, investment requirements and risk profiles. Both companies will have strong balance sheets and cash flows, and will benefit from enhanced financial flexibility and reduced complexity. This will allow each to prioritize and capitalize on unique opportunities presenting the highest growth potential within their respective portfolios.... Read More

May 15, 2015

Baxter International Inc. (NYSE: BAX) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental drug application to establish its Sabinanigo, Spain, facility as an approved manufacturing site for 0.9% Sodium Chloride Injection, USP, for the U.S. market.... Read More

May 14, 2015

Baxter International (NYSE: BAX) today announced the presentation of new data from its growing oncology portfolio at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 29 - June 2, 2015 in Chicago, Ill.... Read More

May 13, 2015

Anthony (Tony) John Culyer, CBE, BA, Hon DEcon, Hon FRCP, FRSA, FMedSci, and Alan Maynard, OBE, BPhil, Hon DSc, Hon LLD, Hon MFPHM, MMEDSci, have been named the 2015 recipients of the William B. Graham Prize for Health Services Research. The Prize, awarded by The Baxter International Foundation and the Association of University Programs in Health Administration (AUPHA), will be presented on June 4, 2015, during the AUPHA Annual Meeting in Miami.... Read More

May 12, 2015

Baxter International Inc. (NYSE:BAX) announced it has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. The acquisition further accelerates the innovation capabilities and the commercial presence of Baxter BioScience in growing oncology markets for rare and orphan diseases. The company gains the leading marketed biologic treatment Oncaspar, the investigational biologic calaspargase pegol, and an established oncology infrastructure with clinical and sales resources. The Oncaspar transaction is expected to close in the third quarter. By mid-year, Baxter expects to establish the BioScience business as a separate, publicly traded, innovation-oriented biopharmaceutical company, Baxalta Incorporated.... Read More

May 11, 2015

DEERFIELD, Ill., May 11, 2015 - Baxter International Inc. (NYSE: BAX) today announced plans to host its 2015 Investor Conferences in advance of the company's separation into two leading global healthcare companies. The Investor Conference for Baxter International Inc. will be held on Monday,... Read More

May 5, 2015

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.52 per Baxter common share. This cash dividend is payable on July 1, 2015 to shareholders of record as of June 1, 2015.... Read More

May 4, 2015

Baxter International Inc. (NYSE:BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) jointly announced that Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of MM-398 (irinotecan liposome injection), also known as "nal-IRI," an investigational treatment for patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The submission follows Merrimack's recent filing of a new drug application (NDA) for this indication with the United States Food and Drug Administration (FDA).... Read More

May 1, 2015

DEERFIELD, Ill., May 1, 2015 - Baxter International Inc. (NYSE: BAX) today announced plans to host its 2015 Investor Conferences in advance of the company's separation into two leading global healthcare companies. The Investor Conference for Baxter International Inc. will be held on Monday, ... Read More

Apr 23, 2015

Baxter International Inc. (NYSE:BAX) today reported first quarter financial results that exceeded the company's previously issued guidance. Baxter reported first quarter net income of $430 million and earnings per diluted share of $0.78, compared to net income of $556 million and earnings per diluted share of $1.01 in the same period last year. First quarter 2015 results include net after-tax special items totaling $120 million (or $0.22 per diluted share), primarily for intangible asset amortization, costs associated with the company's planned separation and the integration of its Gambro AB acquisition, partially offset by a benefit related to the reversal of certain business optimization reserves. First quarter 2014 results included net after-tax charges totaling $96 million (or $0.18 per diluted share).... Read More

Apr 21, 2015

Baxter International Inc. (NYSE:BAX) is celebrating the fifth annual World Primary Immunodeficiency Week Campaign, April 22 - 29, 2015, by collaborating with the International Patient Organisation for Primary Immunodeficiencies (IPOPI) to advance the global state of care for primary immunodeficiencies (PI, defined as a large group of disorders in which part of the body's immune system is missing or does not function properly). World PI Week, for which Baxter was the founding sponsor and remains the lead supporter, is led by a consortium of clinical societies, patient organizations and research foundations from around the world, aiming to raise awareness and improve the diagnosis and treatment for people with PI.... Read More

Apr 21, 2015

Baxter International Inc. (NYSE:  BAX) will webcast its annual meeting of shareholders on Tuesday, May 5, 2015 at 9:00 a.m. Central Time.... Read More

Apr 17, 2015

Today, Baxter International joins the World Federation of Hemophilia (WFH) and its partners in the global hemophilia community to recognize World Hemophilia Day, an annual observation intended to help raise awareness of hemophilia and other bleeding disorders.... Read More

Apr 17, 2015

Baxter International Inc. (NYSE:BAX) today presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1  The data were presented as an Abstract of Distinction during an oral session at the 2015 Scientific Symposium of the Hemostasis and Thrombosis Research Society (HTRS) in New Orleans, La. and expand on the topline data first disclosed in 2014. The trial met its primary efficacy endpoint defined by the number of patients who achieved treatment success for control of bleeding episodes.... Read More

Apr 16, 2015

"We continue to advance BAX 855 as a potential new treatment for hemophilia A patients around the world who are seeking options that support their individual needs," said John Orloff, M.D., vice president and global head of research and development for Baxter BioScience. "With more than a decade of experience with ADVATE and an extensive global presence, our BAX 855 program represents our continued commitment to supporting the hemophilia community, particularly this week as we celebrate World Hemophilia Day with our colleagues around the globe."... Read More

Apr 9, 2015

Baxter International Inc. announced today it is voluntarily recalling select lots of intravenous (IV) solutions to the hospital/user level due to the potential presence of particulate matter. Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number, and composition of the foreign material, and patient's underlying medical condition. In the absence of in-line filtration, these particles may cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization. In high-risk patients this may lead to serious adverse health consequences.... Read More

Apr 7, 2015

Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its first quarter 2015 financial results on Thursday, April 23, 2015, at 7:30 a.m. Central Time. To access the call, please dial 877-894-0694 (domestic) or 347-983-2217 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. The Conference ID is 35112171.... Read More

Apr 2, 2015

The agreement includes NUTRYELT® concentrate solution for infusion (a multi-trace element product) for adults, and SELENIUM and ZINC (single-trace element products).  NUTRYELT® contains nine essential trace elements consistent with the most recent European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines for trace elements.... Read More

Apr 1, 2015

For prescription only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.... Read More

Mar 30, 2015

Baxter Launches Public-Private Partnership to Improve Healthcare Delivery... Read More

Mar 13, 2015

Baxter International Inc. (NYSE:BAX) today announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who develop inhibitors.... Read More

Mar 4, 2015

Baxter International Inc. (NYSE:BAX) and SuppreMol GmbH today announced that Baxter has acquired SuppreMol for EUR 200 million (approximately $225M USD) before working capital and other adjustments. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases.... Read More

Feb 23, 2015

Baxter International Inc. (NYSE:BAX) announced today that Baxalta Incorporated, the biopharmaceutical company that is expected to separate from Baxter in mid-2015, will be headquartered in Northern Illinois at 1200 Lakeside Drive, Bannockburn, Ill.... Read More

Feb 19, 2015

Baxter International Inc. (NYSE:  BAX) announced today that it will present at Barclay's Global Healthcare Conference on Tuesday, March 10 at 9:45 a.m. (CT).... Read More

Feb 17, 2015

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.52 per Baxter common share. The dividend is payable on April 1, 2015 to shareholders of record as of March 11, 2015.... Read More

Feb 12, 2015

Baxter International Inc. (NYSE:BAX) today provided an update on its gene therapy program, including progress on the Phase I/II open-label clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy treatment for hemophilia B, during a sponsored symposium at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland.... Read More

Feb 11, 2015

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A.... Read More

Feb 10, 2015

Baxter International Inc. (NYSE: BAX) announced today that it will present at the Cowen & Company's 35th Annual Health Care Conference on Monday, March 2, 2015 at 2:30 p.m. (CT).... Read More

Jan 29, 2015

Baxter International Inc. (NYSE:BAX) today announced fourth quarter 2014 financial results that exceeded expectations and reported on its progress toward its planned separation into two independent, leading healthcare companies in mid-2015.... Read More

Jan 29, 2015

Baxter International Inc. (NYSE:BAX) today announced fourth quarter 2014 financial results that exceeded expectations and reported on its progress toward its planned separation into two independent, leading healthcare companies in mid-2015.... Read More

Jan 20, 2015

DEERFIELD, Ill., (January 20, 2015) - Baxter International Inc. (NYSE:BAX) today announced the United States Food and Drug Administration (FDA) has approved PHOXILLUM Renal Replacement Solutions (BK4/2.5 and B22K4/0) as replacement solutions in continuous renal replacement therapy (CRRT) to correct electrolyte and acid-base imbalances, and in case of drug poisoning when CRRT is used to remove dialyzable substances. The FDA has granted PHOXILLUM orphan drug designation for use in CRRT.... Read More

Jan 15, 2015

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Palmetto Health in Columbia, South Carolina, is the recipient of the 2014 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare. The healthcare system was named a finalist for the award in 2011.... Read More

Dec 22, 2014

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the approval of BAX111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1... Read More

Dec 18, 2014

Baxter International Inc. (NYSE:  BAX) announced that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 5:00 p.m. (CT).... Read More

Dec 17, 2014

Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its fourth quarter 2014 financial results on Thursday, January 29, 2015, at 7:30 a.m. Central Time. To access the conference call, please dial 877-894-0694 (domestic) or 347-983-2217 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. The Conference ID is 35111298.... Read More

Dec 11, 2014

Baxter International Inc. (NYSE:BAX) announced today it voluntarily initiated a recall in the United States of two lots of 0.9% Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container to the hospital/user level. The recall is being initiated as a result of two complaints (one per lot) of particulate matter that was identified as a fragment of the frangible from the vial adapter. The issue was identified upon standard visual inspection prior to patient administration.... Read More

Dec 10, 2014

Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics, Inc. Financial details were not disclosed.... Read More

Dec 10, 2014

Baxter International Inc. (NYSE:BAX) announced the filing of an initial Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC) in connection with the company's previously announced plan to spin off its biopharmaceutical business. The filing is an important step in creating two premier global healthcare companies: Baxter International Inc., which will focus on lifesaving medical products; and Baxalta Incorporated, which will focus on developing and marketing innovative biopharmaceuticals.... Read More

Dec 9, 2014

Baxter International Inc. (NYSE: BAX) has been named as one of America's most community-minded companies by the Points of Light Foundation's Civic 50 list, and also received recognition for its inclusion and diversity leadership by several external organizations. The company is committed to advancing sustainability in its workplaces and communities, and recently hosted a Workplace Charging for Electric Vehicles workshop for companies interested in providing electric vehicle charging stations for their employees. Additionally, Baxter's Round Lake facility was honored with an Illinois Governor's Sustainability Award for environmental excellence.... Read More

Dec 1, 2014

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].... Read More

Nov 20, 2014

Potassium Chloride is indicated for treatment of potassium deficiency and administered intravenously. Some containers of Product Code 2B0826, Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL, Lot Number P319160, Exp. 06/30/2015, NDC 0338-0709-48 were incorrectly labeled on the overpouch as Highly Concentrated Potassium Chloride Injection, 20 mEq per 100 mL. Products were distributed to customers in the U.S. between June 23, 2014 and October 2, 2014. Unaffected lot numbers can continue to be used according to the instructions for use.... Read More

Nov 13, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 26th Annual Piper Jaffray Healthcare Conference Tuesday, December 2, 2014 at 12:00 p.m. (CT).... Read More

Nov 11, 2014

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.52 per Baxter common share. The dividend is payable on January 2, 2015 to shareholders of record as of December 5, 2014.... Read More

Nov 5, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:30 a.m. (CT).... Read More

Oct 30, 2014

Baxter International Inc. (NYSE:BAX) presented the results of a Phase 2/3 study of its investigational 20 percent concentration subcutaneous immunoglobulin treatment for primary immunodeficiencies (PI) during the biennial congress of the European Society for Immunodeficiencies, held in Prague.... Read More

Oct 24, 2014

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (AHA), a very rare and potentially life-threatening acute bleeding disorder. OBIZUR was granted orphan-drug status by the FDA and its review was prioritized based on AHA's classification as a rare disease and the potential for the treatment to address an important unmet medical need.... Read More

Oct 22, 2014

Baxter International Inc. announced today it is voluntarily recalling two lots of INTRAVIA containers in the U.S. and Canada due to complaints received for particulate matter found inside the fluid path. Intravenous administration of a solution containing sterile particulate matter may lead to adverse health consequences. The extent and severity of harm depends on the size, number, and composition of the foreign material, and patient's underlying medical condition. There have been no reported adverse events associated with this issue to date.... Read More

Oct 22, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 2014 Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:00 a.m. (CT).... Read More

Oct 17, 2014

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced the launch and first shipments of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's subcutaneous immunoglobulin treatment for adult patients with primary immunodeficiency (PI) in the United States. The treatment was approved by the U.S. Food and Drug Administration (FDA) in September of this year.... Read More

Oct 16, 2014

Baxter International Inc. (NYSE:BAX) today posted strong financial results for the third quarter, which exceeded expectations and provided its fourth quarter and full-year 2014 guidance adjusting for the planned divestiture of its vaccines franchise. The company continues to bolster its business portfolios by establishing new collaborations and advancing its new product pipeline with the achievement of significant milestones, and remains on track for the anticipated separation into two independent, leading healthcare companies in mid-2015.... Read More

Oct 9, 2014

Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its third quarter 2014 financial results on Thursday, October 16, 2014, at 7:30 a.m. Central Time.... Read More

Oct 8, 2014

Baxter International Inc. (NYSE: BAX) has been recognized for its sustainability leadership by several external organizations, including the Healthcare Businesswomen's Association's 2014 ACE Award for commitment to advancing women's careers in the healthcare industry and the Dow Jones Sustainability Index. Record participation in environmental and wellness sustainability programs has sparked additional innovative ideas from employees to help the company achieve its sustainability goals.... Read More

Sep 29, 2014

Baxter International Inc. (NYSE:BAX) today announced plans to form a new global innovation and research and development (R&D) center in Cambridge, Mass., for Baxter's biopharmaceuticals business, which is expected to become a separate, independent global company known as Baxalta Incorporated in mid-2015.... Read More

Sep 25, 2014

DEERFIELD, Ill., September 25, 2014 - Baxter International Inc. (NYSE:BAX), will host a quarterly conference call to discuss its third quarter 2014 financial results on Thursday, October 16, 2014, at 7:30 a.m. central time. To access the call, please dial 866-837-9782 (domestic) or 703-639-1420 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.... Read More

Sep 24, 2014

Merrimack Conference Call Scheduled for 8:30 a.m. ET Today... Read More

Sep 16, 2014

Baxter International Inc. announced today it is voluntarily recalling one lot of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826 to the hospital/pharmacy/nurse level. The recall is being initiated due to a labeling error on the shipping cartons in a single lot, which was identified by three customers. Shipping cartons labeled for this specific lot number of Potassium Chloride Injection may contain units of Gentamicin Sulfate Injection, 80 mg in 100 mL, product code 2B0862.... Read More

Sep 15, 2014

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B. RIXUBIS was the first recombinant factor IX (rFIX) approved for routine prophylaxis and control of bleeding episodes in the U.S. for adults living with this chronic condition.... Read More

Sep 12, 2014

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].... Read More

Sep 10, 2014

Baxter International Inc. (NYSE:BAX) announced today that Baxalta Incorporated will be the name of the new, publicly traded biopharmaceutical company that is expected to launch in mid-2015.... Read More

Aug 21, 2014

Baxter International Inc. (NYSE:BAX) today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.... Read More

Aug 19, 2014

Baxter International Inc. (NYSE:BAX) announced today that it plans to expand its state-of-the-art manufacturing facility in Opelika, Ala., to help address the growing global demand for dialyzers, a critical component used in hemodialysis therapy (HD).... Read More

Aug 18, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:25 p.m. (CT).... Read More

Aug 13, 2014

Baxter International Inc. announced today it is voluntarily initiating a recall in the United States of two lots of DIANEAL Low Calcium (2.5mEq/L) Peritoneal Dialysis Solution with 2.5% Dextrose 5000mL (Ambu-Flex II) to the hospital/user level. The recall is being initiated due to the presence of oxidized stainless steel, garment fiber, and PVC particulate matter identified during the manufacturing process.... Read More

Aug 7, 2014

SINGAPORE, 7 August 2014 - Baxter International Inc. (BAX:NYSE) today announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite.... Read More

Aug 4, 2014

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN® [Albumin (Human)], USP, 5% Solution. FLEXBUMIN 5% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns and in patients undergoing cardiopulmonary bypass surgery.... Read More

Aug 4, 2014

SINGAPORE, 7 August 2014 - Baxter International Inc. (BAX:NYSE) today announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite.... Read More

Jul 31, 2014

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.... Read More

Jul 30, 2014

Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for a total cash consideration of $635 million, subject to certain adjustments.... Read More

Jul 29, 2014

Baxter International Inc. (NYSE:BAX) today announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer, Inc. for a total cash consideration of $635 million, subject to certain adjustments.... Read More

Jul 22, 2014

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.52 per Baxter common share. The dividend is payable on October 1, 2014 to shareholders of record as of September 5, 2014.... Read More

Jul 17, 2014

Baxter International Inc. (NYSE:BAX) today reported strong growth across its global franchises in the second quarter, generating sales and earnings that exceeded the company's previously issued guidance. The company also confirmed its financial outlook for 2014, narrowing the guidance range for adjusted earnings per diluted share to $5.10 to $5.20.... Read More

Jul 14, 2014

Baxter International Inc. announced today it is voluntarily recalling four lots of intravenous (IV) solutions to the hospital/user level. These products have been found to contain particulate matter identified as cellulosic fibers and/or plastics. Baxter received four complaints over a period of six months from customers whose visual inspection identified the appearance of visible particulate matter prior to administration to a patient.... Read More

Jul 10, 2014

Baxter International Inc. (NYSE:BAX) today announced the appointment of John Orloff, M.D., as vice president and global head of research and development for Baxter BioScience, effective immediately. Dr. Orloff joins Baxter from Merck Serono Pharmaceuticals, where he served as global head of clinical development. Dr. Orloff will be responsible for advancing the late-stage BioScience pipeline, enhancing the current R&D operating model and pursuing additional innovative opportunities for the business.... Read More

Jul 9, 2014

Baxter International Inc. (NYSE:BAX) today announced the acquisition of AesRx, LLC, a private U.S. biopharmaceutical company focused on orphan drug targets, including the development and commercialization of Aes-103, an investigational prophylactic treatment for sickle cell disease (SCD).... Read More

Jul 7, 2014

Baxter International Inc. (NYSE:BAX) announced that upon completion of the tax-free distribution of the company's biopharmaceuticals business, Robert J. Hombach, currently chief financial officer for Baxter International Inc., will be appointed chief financial officer and will assume additional operational responsibilities for the independent biopharmaceuticals company. Hombach will report to Ludwig N. Hantson, PhD., who will serve as the new company's CEO. James K. Saccaro will rejoin Baxter August 4, 2014, and will assume the role of chief financial officer of Baxter International Inc., reporting to Robert L. Parkinson, Jr., Baxter's chairman and CEO, following completion of the transaction in 2015.... Read More

Jun 26, 2014

Baxter International Inc. (NYSE:BAX), will host a quarterly conference call to discuss its second quarter 2014 financial results on Thursday, July 17, 2014, at 7:30 a.m. central time. To access the call, please dial 866-837-9782 (domestic) or 703-639-1420 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.... Read More

Jun 25, 2014

Baxter International Inc. (NYSE: BAX) has been recognized for its sustainability leadership by several external organizations, including the Healthcare Businesswomen's Association's 2014 ACE Award for commitment to advancing women's careers in the healthcare industry and the Dow Jones Sustainability Index. Record participation in environmental and wellness sustainability programs has sparked additional innovative ideas from employees to help the company achieve its sustainability goals.... Read More

Jun 24, 2014

Baxter International Inc. announced today it is voluntarily recalling one lot of 0.9% Sodium Chloride Injection, USP 1000 mL, a portion of which was released to customers. The recall is being initiated as a result of particulate matter found near the administration port.... Read More

Jun 3, 2014

Baxter International Inc. (NYSE:BAX) today announced the presentation of clinical data supporting the safety and efficacy of the VIVIA haemodialysis (HD) system. Results from two studies conducted in a clinical setting showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices. The VIVIA system, designed to deliver High Dose HD in the home, completed the CE marking process (market approval) in Europe, December 2013.... Read More

May 28, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014 at 4:00 p.m. (CT).... Read More

May 28, 2014

Baxter International Inc. (NYSE:BAX) continues to build upon its global leadership position in hemophilia with ADVATE [Antihemophilic Factor (Recombinant)], the first recombinant treatment with no human or animal protein additives for patients with hemophilia A.  ADVATE continues to be the most prescribed full-length recombinant FVIII worldwide, with more than 10 years of real-world experience and over 17 billion units distributed.... Read More

May 21, 2014

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the company's investigational subcutaneous treatment for patients with primary immunodeficiency (PI).... Read More

May 13, 2014

A preeminent economist whose research interests focus primarily on federal and state health policy, Dr. Altman is a former dean of The Heller School for Social Policy & Management and Sol C. Chaikin Professor of National Health Policy at Brandeis University. He has an M.A. and Ph.D. degree in Economics from University of California Los Angeles and taught at Brown University and the Graduate School of Public Policy at University of California at Berkeley.... Read More

May 12, 2014

Baxter International Inc. (NYSE: BAX) showcased its commitment to innovation in hemophilia today with the presentation of new data from 60 oral and poster presentations during the 2014 World Federation of Hemophilia (WFH) World Congress in Melbourne, Australia (May 11-15). The data include safety, efficacy and immunogenicity findings on Baxter's global leading brands and new treatments for hemophilia A, von Willebrand disease and other coagulation disorders.... Read More

May 8, 2014

Baxter International Inc. (NYSE:BAX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation SIGMA Spectrum Infusion Pump with Master Drug Library. Enhancements to the infusion pump include increased capacity of the master drug library, which is safety software that enables a hospital to maintain a customized in-house library of facility-defined dosing parameters for infusions to minimize the likelihood of drug errors during care. In addition, new asset-tracking capabilities will allow hospitals to effectively locate, manage and deploy SIGMA Spectrum inventory, helping to ensure efficient allocation of hospital assets.... Read More

May 5, 2014

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.52 per Baxter common share, representing a six percent increase.... Read More

Apr 29, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 3:40 p.m. (CT).... Read More

Apr 24, 2014

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 3:10 p.m. (CT).... Read More

Apr 23, 2014

About Baxter International Inc.... Read More

Apr 22, 2014

DEERFIELD, Ill., April 22, 2014 - Baxter International Inc. (NYSE:BAX) recognizes World PI Week, a global campaign being celebrated April 22 - 29, 2014. Now in its fourth year, the campaign aims to raise awareness and improve diagnosis and treatment of primary immunodeficiencies (PI).

"B... Read More

Apr 21, 2014

Baxter International Inc. (NYSE:  BAX) will webcast its annual meeting of shareholders on Tuesday, May 6, 2014 at 9:00 a.m. Central Time.... Read More

Apr 17, 2014

Baxter International Inc. (NYSE:BAX) today reported first quarter financial results that exceeded the company's previously issued guidance and confirmed its full-year 2014 financial outlook.... Read More

Apr 16, 2014

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application (BLA) for HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the company's investigational subcutaneous treatment for patients with primary immunodeficiency (PI).... Read More

Apr 16, 2014

Baxter International Inc. (NYSE:BAX) marks World Hemophilia Day, observed annually by the World Federation of Hemophilia and the global hemophilia community to raise awareness of the disease and other bleeding disorders. This year, the observance encourages the community to, "Speak out. Create change."... Read More

Apr 15, 2014

Baxter International Inc. (NYSE:BAX) today announced topline results from a Phase III clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.... Read More

Apr 10, 2014

Baxter International Inc. (NYSE: BAX) announced  educational collaborations with local institutions to prepare the current and future workforce for careers, and was recently recognized for safety performance. The company and its philanthropic arm, The Baxter International Foundation, also announced their 2013 charitable giving. ... Read More

Apr 3, 2014

Baxter International Inc. (NYSE:BAX), will host a quarterly conference call to discuss its first quarter 2014 financial results on Thursday, April 17, 2014, at 7:30 a.m. Central Time.  To access the call, please dial 866-837-9782 (domestic) or 703-639-1420 (international).  Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. ... Read More

Apr 2, 2014

Baxter International Inc. (NYSE:BAX) and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham's outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham's developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.... Read More

Mar 27, 2014

Baxter International Inc. (NYSE:BAX) today announced plans to create two separate, independent global healthcare companies one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products.  Both will be global leaders in their respective markets.... Read More

Mar 5, 2014

DEERFIELD, Ill.,- Baxter International Inc. announced today it has initiated a voluntary recall in the United States of a single lot of DIANEAL PD-2 Peritoneal Dialysis Solution with 1.5% Dextrose 6000mL (Ambu-Flex II) to the hospital/user level.  The recall is being initiated as a result of complaints of particulate matter, identified as mold, resulting from a leak in the container.... Read More

Feb 27, 2014

Baxter International Inc. (NYSE:BAX) today presented clinical data on Baxter's leading recombinant factor VIII treatment, including interim data from the first year of observation from the AHEAD (ADVATE HaEmophilia A Database) study, a four-year outcomes registry of hemophilia A patients treated with ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method]. These data were presented during the European Association for Haemophilia and Allied Disorders (EAHAD) meeting in Brussels, Belgium.... Read More

Feb 27, 2014

Baxter International Inc. (NYSE: BAX) announced today that it will present at Barclay's Global Healthcare Conference on Tuesday, March 11th at 7:00 a.m. (CT).... Read More

Feb 18, 2014

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share. The dividend is payable on April 1, 2014 to shareholders of record as of March 7, 2014.... Read More

Feb 13, 2014

Baxter International Inc. (NYSE: BAX) announced today that it will present at the Cowen & Company's 34th Annual Health Care Conference on Monday, March 3, 2014 at 2:30 p.m. (CT).... Read More

Feb 10, 2014

Baxter International Inc. (NYSE: BAX) announced today that it will present at the Citi 2014 Global Healthcare Conference on Tuesday, February 25, 2014 at 1:40 p.m. (CT) and the 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at 8:00 a.m. (CT)... Read More

Jan 30, 2014

Baxter International Inc. (NYSE:BAX) has restructured its ongoing agreement with Xenetic Biosciences, Inc. (OTCBB: GAIFD) for the development of BAX 826, a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness. This program complements the company's current development programs, which are focused on improving the pharmacokinetic profile and extending the half-life of blood coagulation factors, including Factor VIII.... Read More

Jan 23, 2014

Baxter International Inc. (NYSE:BAX) today announced financial results for the fourth quarter of 2013, and provided its financial outlook for the first quarter and full-year 2014.... Read More

Jan 16, 2014

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Crozer-Keystone Health System in Delaware County, Pa. is the recipient of the 2013 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 6, 2014

Baxter International Inc. (NYSE:  BAX) announced that it will present at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 5:00 p.m. (CT).... Read More

Jan 6, 2014

Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its fourth quarter 2013 financial results on Thursday, January 23, 2014, at 7:30 a.m. Central Time. To access the call, please dial 866-837-9782 (domestic) or 703-639-1420 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.... Read More

Jan 3, 2014

Baxter International Inc. announced today it has initiated a voluntary recall in the United States of two lots of CLINIMIX and one lot of CLINIMIX E Injection parenteral nutrition products to the user level due to complaints of particulate matter found in the products. If infused, particulate matter may result in blockages of blood vessels, which can result in stroke, heart attack, or damage to other organs such as the kidney or liver. There is also the possibility of allergic reactions, local irritation, and inflammation in tissues and organs. There have been no reported adverse events associated with this issue to date, and the root cause of this voluntary recall has been identified and resolved.... Read More

Dec 23, 2013

Baxter International Inc. announced today it has initiated a voluntary recall to the hospital/user level of one lot of 5% Dextrose Injection, USP and four lots of 0.9% Sodium Chloride Injection, USP due to particulate matter found in the solutions.... Read More

Dec 20, 2013

DEERFIELD, Ill., (December 20, 2013) - Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.... Read More

Dec 19, 2013

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.... Read More

Dec 10, 2013

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.  Phase 2/3 data supporting the submission were presented at the American Society of Hematology's (ASH) 55th Annual Meeting in New Orleans, LA.... Read More

Dec 9, 2013

Indications for RIXUBIS... Read More

Dec 2, 2013

DEERFIELD, Ill., and SAN DIEGO, DECEMBER 2, 2013-Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today that Baxter has completed submission of an amended biologics license application (BLA) to the United States Food and Drug Administration (FDA) to re-initiate the review process for approval of HyQvia [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] facilitated subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI).... Read More

Nov 27, 2013

Baxter International Inc. announced today it has initiated a voluntary recall of one lot of Nitroglycerin in 5% Dextrose Injection due to particulate matter found in one vial. If infused, particulate matter could lead to potential venous and/or arterial thromboembolism (blockage of blood vessels.) Other adverse events associated with injection of particulate matter include inflammation due to foreign material, particularly in the lungs, and local irritation of blood vessels.... Read More

Nov 15, 2013

Baxter International Inc. (NYSE:BAX) and Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today jointly announced that they have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder.... Read More

Nov 14, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 25th Annual Piper Jaffray Healthcare Conference Tuesday, December 3, 2013 at 12:00 p.m. (CT).... Read More

Nov 13, 2013

Baxter International Inc. (NYSE:BAX) today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.... Read More

Nov 12, 2013

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share.  The dividend is payable on January 3, 2014 to shareholders of record as of December 6, 2013.... Read More

Oct 31, 2013

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of RIXUBIS, recombinant factor IX (nonacog gamma) for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. Hemophilia B, also known as Christmas disease, is the second most common type of hemophilia and results from insufficient amounts of clotting factor IX, a naturally occurring protein in blood that helps to control bleeding.1 RIXUBIS was approved for adult patients and launched in the United States and Puerto Rico earlier in 2013.... Read More

Oct 29, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 2013 Credit Suisse Healthcare Conference on Wednesday, November 13, 2013 at 9:30 a.m. (CT).... Read More

Oct 23, 2013

Baxter International Inc. (NYSE:BAX) today announced the launch of HEMOPATCH Sealing Hemostat, a novel collagen-based hemostatic device, following CE mark approval in Europe. HEMOPATCH is a resorbable hemostatic device used for surgical procedures when control of bleeding by pressure, ligature or conventional procedures is either ineffective or impractical. The development of HEMOPATCH combined Baxter's expertise in collagen, internal coagulation processes, and PEG (polyethylene glycol) technology platforms.... Read More

Oct 21, 2013

Baxter International Inc. (NYSE: BAX) continued to advance sustainability within the organization by adding Business Resource Groups (BRGs) that support an inclusive and diverse work environment and encouraging employee health and wellness through its recent BeWell@Baxter Exercise Challenge. The company was also recently recognized in various sustainability rankings and awards, including the 2013 CPA-Zicklin Index of Corporate Political Accountability and Disclosure, the Dow Jones Sustainability Index, and the Golden Peacock Global Award for Excellence in Corporate Governance from India's Institute of Directors.... Read More

Oct 17, 2013

Baxter International Inc. (NYSE:BAX) today posted solid financial results for the third quarter which met expectations as the company further augmented its portfolio with the acquisition of Gambro AB, and continued to advance its new product pipeline by launching new products, achieving multiple regulatory milestones, and establishing new collaborations. The company also provided guidance for the fourth quarter and confirmed its full-year 2013 financial outlook.... Read More

Oct 15, 2013

Baxter International Inc. (NYSE: BAX) today issued its 14th consecutive Sustainability Report, available at http://sustainability.baxter.com, detailing the company's commitment and progress to creating lasting social, environmental and economic value by addressing the needs of stakeholders worldwide.... Read More

Oct 2, 2013

 ... Read More

Sep 19, 2013

Baxter International Inc. announced today it has initiated a voluntary recall of two lots of its Dual Luer Lock Caps (Product Code 2C6250, Lots 10043 and 10044) because of the presence of loose particulate matter found in the packaging.  Particulate matter entering the fluid path from the Luer Lock Caps may result in thrombotic and embolic events, including: pulmonary embolism, myocardial infarction and stroke. There have been no reported complaints associated with this issue, however embolic events may not be easily attributed to such particulate matter. The root cause has been identified and resolved. The U.S. Food and Drug Administration (FDA) has designated this as a Class I recall.... Read More

Sep 9, 2013

Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has elected Todd S. Young as treasurer and a corporate officer of the company.... Read More

Sep 6, 2013

Baxter International Inc. (NYSE: BAX) today announced that the company has successfully completed the acquisition of Gambro AB, a privately held global medical technology company and leader in dialysis products based in Lund, Sweden. The transaction further enhances Baxter's global renal leadership and provides the company with a comprehensive product and therapies portfolio to meet the needs of patients in the large and growing dialysis market.... Read More

Sep 3, 2013

Baxter International Inc. (NYSE:BAX) and Coherus Biosciences, Inc. today announced that they have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and certain other markets. Additionally, the agreement allows for the expansion of the collaboration to include another product. Biosimilars are intended to be used in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases and have the potential to reduce costs and expand patient access.... Read More

Aug 22, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3:25 p.m. (CT).... Read More

Aug 8, 2013

Ferrell has been the principal investigator of a project funded by the National Cancer Institute called “Palliative Care for Quality of Life and Symptom Concerns in Lung Cancer.” The End-of-Life Nursing Education Consortium (ELNEC) project was developed after her research findings revealed that end-of-life care was absent in nursing education curricula. As the principal investigator of ELNEC, she developed curricula in end-of-life/palliative care for undergraduate and graduate nursing programs; for oncology, pediatric, critical care, and geriatric nursing; and for veterans with life-threatening illnesses.... Read More

Jul 31, 2013

Baxter International Inc. (NYSE:BAX) and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids. With this collaboration, Baxter will complement its leading global parenteral nutrition portfolio, and provide global commercial capabilities and clinical development.... Read More

Jul 23, 2013

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share. The dividend is payable on October 1, 2013 to shareholders of record as of September 6, 2013.... Read More

Jul 22, 2013

Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method, (in the EU, ADVATE, octocog alfa)] to include findings of the Phase IV prophylaxis study.... Read More

Jul 18, 2013

Baxter International Inc. (NYSE:BAX) today announced solid financial results for the second quarter, with earnings that exceeded the company's previously issued guidance, and confirmed its full-year 2013 financial outlook.... Read More

Jul 16, 2013

Baxter International Inc. (NYSE:BAX) today presented  additional data from the Phase III Gammaglobulin Alzheimer's Partnership (GAP) study, including select analyses of subgroups, biomarker and imaging data during the Alzheimer's Association International Conference (AAIC) in Boston, Mass. The GAP study was conducted by Baxter and the Alzheimer's Disease Cooperative Study (ADCS), a clinical trial consortium supported by the United States National Institute on Aging at the National Institutes of Health. ... Read More

Jul 8, 2013

 ... Read More

Jul 5, 2013

Baxter International Inc. (NYSE: BAX) today announced data featuring ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method], a leading recombinant treatment available worldwide, during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The first study identifies a correlation between peak levels of factor VIII (FVIII) in the body and the efficacy of treatment, indicating that frequency of peaks may be important when choosing hemophilia treatments. A second presentation reinforces that for both hemophilia patients and parents, efficacy through reduction in bleeds considerably outweighs infusion convenience as the primary treatment priority.... Read More

Jul 2, 2013

Baxter International Inc. (NYSE:BAX) today presented two comprehensive analyses supporting the proven clinical and real-world results of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The presentations include two complementary studies of the ADVATE profile, including an analysis of post-marketing data from approximately 1,200 hemophilia A patients across 15 countries as well as safety findings from a 10-year database of 12 clinical trials.... Read More

Jun 27, 2013

Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control of bleeding episodes, and perioperative management in adults with hemophilia B. RIXUBIS is the first new recombinant factor IX (rFIX) approved for hemophilia B in more than 15 years and is the only rFIX indicated for both routine prophylaxis and control of bleeding episodes in the U.S. for adult patients living with this chronic condition. Hemophilia B is the second most common type of hemophilia and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding.1... Read More

Jun 26, 2013

Baxter International Inc. (NYSE: BAX) today issued its 14th consecutive Sustainability Report, available at http://sustainability.baxter.com, detailing the company's commitment and progress to creating lasting social, environmental and economic value by addressing the needs of stakeholders worldwide.... Read More

May 25, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Deutsche Bank 38th Annual dbAccess Health Care Conference on Wednesday, May 29, 2013 at 7:00 a.m. (CT).... Read More

May 23, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11, 2013 at 4:40 p.m. (CT).... Read More

May 21, 2013

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the European Commission has granted Baxter marketing authorization in all European Union (EU) Member States for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies.... Read More

May 9, 2013

Dorothy P. Rice, Sc.D., has been named the 2013 recipient of the William B. Graham Prize for Health Services Research.  The Prize, funded by The Baxter International Foundation and managed by the Association of University Programs in Health Administration (AUPHA), will be awarded on June 20, 2013 during the AUPHA Annual Meeting in Monterey, Calif.... Read More

May 7, 2013

Baxter International Inc. (NYSE:BAX) today announced it is increasing its dividend for shareholders by nine percent.... Read More

May 7, 2013

Baxter International Inc. (NYSE:BAX) today announced that its Phase III clinical study of immunoglobulin (IG) did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease. The Gammaglobulin Alzheimer's Partnership (GAP) study was conducted by Baxter in collaboration with the Alzheimer's Disease Cooperative Study (ADCS), a clinical trial consortium supported by the United States National Institute on Aging in the National Institutes of Health.... Read More

May 6, 2013

Baxter International Inc. (NYSE:BAX) today announced it is increasing its dividend for shareholders by nine percent.... Read More

Apr 25, 2013

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Bank of America Merrill Lynch 2013 Health Care Conference  on Tuesday, May 14, 2013 at 5:40 p.m. (CT).... Read More

Apr 24, 2013

Baxter International Inc. (NYSE:BAX) today announced Phase I/II data evaluating the safety and immunogenicity of its investigational Lyme disease candidate vaccine during the National Foundation for Infectious Diseases 16th Annual Conference on Vaccine Research in Baltimore, Md. In this Phase I/II study, the candidate vaccine was shown to induce substantial antibody titers against all targeted species of Borrelia, the causative agent of Lyme disease, the most prevalent tick-transmitted disease, which is reported in the United States and throughout much of the European Union.... Read More

Apr 23, 2013

Baxter International Inc. (NYSE:  BAX) will webcast its annual meeting of shareholders on Tuesday, May 7, 2013, at 9:00 a.m. Central Time.... Read More

Apr 18, 2013

Baxter International Inc. (NYSE:BAX) today reported first quarter financial results in line with the company's previously issued guidance and confirmed its full-year 2013 financial outlook.... Read More

Apr 16, 2013

Baxter International Inc. (NYSE:BAX) today announced its continued commitment to the hemophilia community to close the gap in hemophilia care and the company's vision to pursue a bleed-free world for people living with this debilitating disorder on World Hemophilia Day.... Read More

Apr 2, 2013

Baxter International Inc. (NYSE: BAX) is incorporating innovative technologies and has recently established new partnerships in its commitment to environmental sustainability and increasing access to healthcare. Recently the company initiated installation of a trigeneration unit at its Toongabbie, Australia manufacturing facility, and developed strategic partnerships to decrease barriers to care in rural China and optimize environmentally responsible product transportation.  The company also announced its 2012 charitable giving figures and community support initiatives.... Read More

Mar 28, 2013

In June 2012, Baxter announced that it entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's Biological Nano Particles (BNP), an advanced recombinant adeno-associated virus- (rAAV-) based gene therapy technology that has shown potential therapeutic benefit in early studies. The patient dosing is the first clinical milestone from the collaboration.  ... Read More

Mar 27, 2013

 ... Read More

Mar 22, 2013

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC, 10%) and recombinant human hyaluronidase, which facilitates the dispersion and absorption of the IGSC. ... Read More

Mar 22, 2013

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC, 10%) and recombinant human hyaluronidase, which facilitates the dispersion and absorption of the IGSC. ... Read More

Feb 27, 2013

 ... Read More

Feb 26, 2013

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.... Read More

Feb 19, 2013

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.45 per Baxter common share.  The dividend is payable on April 1, 2013 to shareholders of record as of March 8, 2013.... Read More

Feb 7, 2013

 ... Read More

Jan 24, 2013

Baxter Provides Financial Outlook For 2013... Read More

Jan 24, 2013

Baxter International Inc. (NYSE:BAX) announced today that it has agreed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma S.A.S. in conjunction with Inspiration's ongoing bankruptcy proceedings. The transaction is subject to bankruptcy court and regulatory approvals.... Read More

Jan 23, 2013

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, St. Joseph's/Candler Health System in Savannah, Ga. is the recipient of the 2012 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 16, 2013

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Crozer-Keystone Health System in Delaware County, Pa. is the recipient of the 2013 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 14, 2013

 ... Read More

Jan 8, 2013

Baxter International Inc. (NYSE:BAX) today announced pivotal Phase III study results evaluating the efficacy and safety of routine prophylaxis compared to on-demand treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors. Top-line results from the study showed a reduced median annual bleed rate (ABR) from 28.7 during FEIBA NF on-demand treatment to 7.9 during FEIBA NF prophylactic treatment (a 72.5% reduction). The Phase III study will form the basis of a biologics license application (BLA) to be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of 2013.... Read More

Jan 7, 2013

Baxter International Inc. (NYSE:BAX) today announced it has submitted an Investigational New Drug (IND) application for its investigational hemophilia A treatment BAX 855 with the U.S. Food and Drug Administration, following positive results from a Phase I trial. BAX 855 is a full-length longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] the most widely chosen rFVIII in the world. Baxter expects to start enrollment of adult patients in its Phase II/III study in the first quarter of 2013.... Read More

Dec 20, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013 at 3:00 p.m. (PT).... Read More

Dec 10, 2012

Baxter International Inc. (NYSE:BAX) today announced pivotal Phase I/III study results evaluating the safety and efficacy of BAX 326, an investigational recombinant factor IX (rFIX) protein, for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age. The data were presented at the 54th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta. BAX 326 was recently granted orphan-drug designation by the U.S. Food and Drug Administration (FDA), a special status given to a product that when approved, will address an unmet need for people with a rare disease or condition. Data supporting the prophylaxis indication, which is the basis for the orphan drug designation, was included in the biologics license application (BLA).... Read More

Dec 4, 2012

Transaction Supports Accelerated Sales and Earnings Growth Over Baxter's Long-Range Financial Plan... Read More

Nov 13, 2012

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.45 per Baxter common share. The dividend is payable on January 3, 2013 to shareholders of record as of December 7, 2012.... Read More

Nov 8, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 24th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27th  at 12:00 p.m. (CT).... Read More

Nov 5, 2012

Baxter International Inc. (NYSE: BAX) has ranked first among U.S. healthcare companies in Newsweek magazine's Green Rankings for the fourth time since the list's inception in 2009. Baxter has also been named the Medical Products Industry Leader of the Dow Jones Sustainability World Index (DJSI World) and the Dow Jones Sustainability North America Index (DJSI North America) for the 11th year since the launch of the DJSI in 1999. These and other recent recognitions underscore Baxter's dedication to incorporating sustainability into its operations and business objectives.... Read More

Nov 1, 2012

Baxter International Inc. (NYSE:BAX) today announced an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A. Hemophilia A is a genetic condition in which the body does not produce enough clotting protein factor VIII.  It is estimated that more than 10,000 people in Brazil are living with hemophilia A, and today the vast majority are treated with plasma-derived FVIII therapy.1... Read More

Oct 31, 2012

Baxter International Inc. (NYSE:BAX) today announced an exclusive 20-year partnership with Hemobrás (Empresa Brasileira de Hemoderivados e Biotechnologia) to provide hemophilia patients in Brazil greater access to recombinant factor VIII (rFVIII) therapy for the treatment of hemophilia A. Hemophilia A is a genetic condition in which the body does not produce enough clotting protein factor VIII.  It is estimated that more than 10,000 people in Brazil are living with hemophilia A, and today the vast majority are treated with plasma-derived FVIII therapy.1... Read More

Oct 24, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Credit Suisse 21st Annual Healthcare Conference on Wednesday, November 14, at 9:30 a.m. (CT).... Read More

Oct 18, 2012

Baxter International Inc. (NYSE:BAX) today reported third quarter net income of $583 million, or $1.06 per diluted share. This compares to net income in the same period last year of $576 million, or $1.01 per diluted share, reflecting an increase of 5 percent on a per share basis. Baxter's third quarter 2012 financial results included an after-tax research and development charge of $45 million (or $0.08 per diluted share) associated with the company's recently announced European licensing agreement with Onconova Therapeutics, Inc. Financial results from the third quarter 2011 included an after-tax charge of $48 million (or $0.08 per diluted share). ... Read More

Oct 9, 2012

Baxter International Inc. (NYSE:BAX) will host its 2012 Investor Conference today in Chicago, and during the conference, the company plans to provide its five-year long-range financial outlook, update investors on its innovation pipeline, and outline the company's key growth strategies.  ... Read More

Sep 27, 2012

Baxter International Inc. (NYSE:BAX) today announced it has appointed two new members to its Board of Directors, Uma Chowdhry, PhD, and Thomas F. Chen. The appointments are effective November 2012.... Read More

Sep 27, 2012

 ... Read More

Sep 19, 2012

Baxter International Inc. (NYSE:  BAX) previously announced that it will host its 2012 Investor Conference on Tuesday, October 9, 2012 at the Ritz-Carlton Hotel in Chicago, IL, from 8:00 a.m. until approximately 3:30 p.m. CT.... Read More

Sep 19, 2012

DEERFIELD, Ill., and NEWTOWN, PA., SEPTEMBER 19, 2012- Baxter International Inc. (NYSE:BAX) and Onconova Therapeutics, Inc. today announced that they have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a Phase III study for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes (MDS) and in a Phase II/III study for pancreatic cancer.... Read More

Sep 5, 2012

Baxter International Inc. (NYSE:  BAX) previously announced that it will host its 2012 Investor Conference on Tuesday, October 9, 2012 at the Ritz-Carlton Hotel in Chicago, IL, from 8:00 a.m. until approximately 3:30 p.m. CT.... Read More

Sep 5, 2012

Baxter International Inc. (NYSE:BAX) today announced that the company has begun dosing patients with malignant solid tumors in a Phase I clinical trial of a monoclonal antibody, representing the company's efforts to extend its oncology portfolio with advanced biological research and development.... Read More

Sep 4, 2012

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.... Read More

Aug 22, 2012

DEERFIELD, Ill., August 22, 2012  - Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, at 2:00 p.m. (CT) or 3:00 p.m. (ET).... Read More

Aug 1, 2012

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for HyQ, an investigational combination immunoglobulin product for the treatment of patients with primary immunodeficiencies (PI) that includes Immune Globulin (IG) Infusion 10% (Human) and Recombinant Human Hyaluronidase.... Read More

Jul 25, 2012

Baxter International Inc. (NYSE:BAX) today announced a 34 percent increase in its dividend rate and a new share repurchase program. ... Read More

Jul 19, 2012

Baxter International Inc. (NYSE:BAX) today announced that it has entered into a manufacturing services agreement with Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation) in the Netherlands that will provide Baxter up to 1.6 million liters of incremental plasma fractionation capacity annually to support global growth of plasma-derived treatments.... Read More

Jul 19, 2012

Baxter International Inc. (NYSE:BAX) today announced financial results for the second quarter and confirmed its full-year 2012 financial outlook.... Read More

Jul 17, 2012

Baxter International Inc. (NYSE:BAX) today announced that it has entered into a manufacturing services agreement with Stichting Sanquin Bloedvoorziening (Sanquin Blood Supply Foundation) in the Netherlands that will provide Baxter up to 1.6 million liters of incremental plasma fractionation capacity annually to support global growth of plasma-derived treatments.... Read More

Jul 16, 2012

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved a new 4000 IU dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].  ADVATE is a full-length recombinant factor VIII (FVIII) product that is indicated for the control and prevention of bleeding episodes in patients with hemophilia A. The new 4000 IU dosage strength provides the convenience of a single vial dosing opportunity for many adult patients, including some patients on a dosing schedule of every three days for prophylactic treatment with ADVATE.... Read More

Jun 27, 2012

Baxter International Inc. (NYSE: BAX) today issued its 2011 Sustainability Report, marking the 13th consecutive year the company has released a report about its social, environmental and economic performance. The report, available at http://sustainability.baxter.com, features progress toward the company's sustainability priorities and goals and its commitment to addressing the needs of stakeholders worldwide.... Read More

Jun 26, 2012

 ... Read More

Jun 25, 2012

Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN).  This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.... Read More

Jun 18, 2012

DEERFIELD, Ill. (June 18, 2012) - Baxter International Inc. (NYSE: BAX) today announced its SIGMA Spectrum Infusion System has received the "Best in KLAS" award for the second consecutive time in the Smart Pumps Large Volume Pump1 category of the 2012 Best in KLAS Awards: Medical Equipment & Infrastructure report.  This "Best in KLAS" award represents the opinions of healthcare clinicians who use smart infusion systems and hospital executives and managers who make purchasing decisions in U.S. hospitals.  Receiving the "Best in KLAS" award indicates a high level of customer satisfaction with the SIGMA Spectrum Infusion System and its support services.... Read More

Jun 4, 2012

Baxter International Inc. (NYSE:BAX) today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of  potential treatments for hemophilia B utilizing Chatham's gene therapy technology. ... Read More

May 30, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the William Blair & Company 32nd Annual Growth Stock Conference on Thursday, June 14, 2012, at 8:40 a.m. CT.... Read More

May 25, 2012

PARIS, France (May 25, 2012) — Baxter International Inc. (NYSE: BAX) today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids (fats and cholesterol).  The combined results were presented as a late-breaking presentation at the 49th Annual European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) congress in Paris. ... Read More

May 23, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012, at 2:00 p.m. PT.... Read More

May 16, 2012

DEERFIELD, Ill, May 16, 2012- Baxter International Inc. (NYSE:BAX) today announced  the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA). It is estimated that more than 50,000 people in China are living with hemophilia A.... Read More

May 7, 2012

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.335 per Baxter common share. ... Read More

May 2, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Bank of America Merrill Lynch 2012 Healthcare Conference on Wednesday, May 16, 2012, at 11:20 a.m. PT.... Read More

May 1, 2012

Mark V. Pauly, Ph.D., has been named the 2012 recipient of the William B. Graham Prize for Health Services Research. The Prize, funded by The Baxter International Foundation and managed by the Association of University Programs in Health Administration (AUPHA), will be awarded on May 31, 2012 during the AUPHA Annual Meeting in Minneapolis, Minn.... Read More

Apr 27, 2012

IMPORTANT RISK INFORMATION... Read More

Apr 26, 2012

Baxter International Inc. (NYSE:BAX) announced today it has exercised its option and completed the purchase of SIGMA International General Medical Apparatus, LLC., a privately held company based in Medina, New York, by acquiring the remaining 60 percent of the company for a cash payment of approximately $90 million.  In 2009, Baxter entered into an agreement with SIGMA for the exclusive global distribution of its infusion pumps, a 40 percent equity stake in SIGMA, and an option to purchase the remaining 60 percent of SIGMA.... Read More

Apr 24, 2012

The live webcast of Baxter's presentation can be accessed from the Baxter corporate website at www.baxter.com and will be available for replay through June 8, 2012.... Read More

Apr 23, 2012

Baxter International Inc. (NYSE:  BAX) will webcast its annual meeting of shareholders on Tuesday, May 8, 2012, at 9:00 a.m. Central Time.... Read More

Apr 19, 2012

Baxter International Inc. (NYSE:BAX) today posted solid first quarter financial results which exceeded the company's previously issued revenue and earnings per share (EPS) guidance. ... Read More

Apr 19, 2012

Baxter International Inc. (NYSE:BAX), a global leader in biologic medical therapies, today announced it will build a new state-of-the-art manufacturing facility in Georgia to support growth of its plasma-based treatments. These therapies include treatments for immune disorders, trauma and other critical conditions.... Read More

Apr 16, 2012

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the U.S. Food and Drug Administration (FDA) is requesting additional information to complete its review of the HyQ Biologics License Application (BLA).... Read More

Mar 22, 2012

 ... Read More

Mar 21, 2012

Baxter International Inc. (NYSE: BAX) and The Baxter International Foundation, the philanthropic arm of Baxter, today announced combined charitable giving of more than $80 million in 2011. The company was also recently recognized for employee inclusion and diversity development programs, initiatives to provide educational opportunities to youth in need and overall sustainability performance.... Read More

Mar 2, 2012

Baxter International Inc. (NYSE:BAX) announced today that the European Commission (EC) has granted marketing authorization for VEPACEL in all European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway. ... Read More

Mar 2, 2012

Baxter International Inc. (NYSE: BAX) today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies (PI). The company also introduced HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], as the submitted brand name for the investigational product, previously referred to as HyQ. Posters and oral presentations regarding the HyQvia clinical program will be given during the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual meeting in Orlando.... Read More

Feb 29, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at Barclays Capital 2012 Global Healthcare Conference on Wednesday, March 14, 2012, at 10:15 a.m. (ET).... Read More

Feb 28, 2012

Baxter International Inc. (NYSE:BAX) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).... Read More

Feb 21, 2012

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.335 per Baxter common share.... Read More

Feb 20, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Cowen and Company 32nd Annual Healthcare Conference on Monday, March 5, 2012, at 1:30 p.m. ET.... Read More

Feb 15, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Citi 2012 Global Healthcare Conference on Wednesday, February 29, 2012, at 10:00 a.m. (ET).... Read More

Feb 14, 2012

Baxter International Inc. (NYSE:BAX) announced today that the company has completed its planned acquisition of Synovis Life Technologies, Inc. (NASDAQ: SYNO), following approval of the transaction by Synovis shareholders.  The acquisition expands Baxter's regenerative medicine and BioSurgery franchise by adding biological and mechanical products from Synovis used for soft tissue repair and microsurgery in a variety of surgical procedures.... Read More

Feb 13, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will host its 2012 Investor Conference on Tuesday, October 9, 2012 at the Ritz-Carlton Hotel in Chicago, IL.... Read More

Feb 2, 2012

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, 2012, at 1:00 p.m. (CT) or 2:00 p.m. (ET).... Read More

Jan 30, 2012

Baxter International Inc. (NYSE:BAX) announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical. TISSEEL is effective in heparinized patients. TISSEEL mimics the final stages of the body's own blood clotting cascade, creating a clot that adheres to the wound surface and helps achieve hemostasis.... Read More

Jan 26, 2012

Company Achieves Record Sales and Earnings in 2011... Read More

Jan 24, 2012

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Mt. Ascutney Hospital and Health Center (MAHHC) in Windsor, Vt., is the recipient of the 2011 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 23, 2012

Baxter International Inc. (NYSE:BAX) today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] (marketed as KIOVIG outside the United States and Canada), for the treatment of mild to moderate Alzheimer's disease. The company plans to initiate a second, confirmatory Phase III trial in the first quarter of 2012, having satisfactorily completed a futility analysis in its first Phase III trial.... Read More

Jan 9, 2012

Baxter International Inc. (NYSE:BAX) announced today that Jean-Luc Butel has been appointed corporate vice president and president, international, reporting to Robert L. Parkinson, Jr., chairman and chief executive officer. He will assume his new role on February 20, 2012.... Read More

Jan 9, 2012

Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for the treatment of multifocal motor neuropathy (MMN). The product, marketed as KIOVIG outside the United States and Canada, was approved for the MMN indication in Europe in 2011.... Read More

Jan 5, 2012

Baxter International Inc. (NYSE:BAX) today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.  BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.... Read More

Jan 4, 2012

Baxter International Inc. (NYSE:BAX) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 2 million shares, or approximately 0.35 percent, of Baxter's outstanding common stock at a price of $46.10 per share in cash. The offer price was 4.67 percent below the $48.36 closing price of Baxter's common stock on December 15, 2011, the day prior to the offer. TRC's offer is subject to a number of conditions, including TRC's ability to obtain financing necessary to consummate the offer.... Read More

Jan 4, 2012

 ... Read More

Dec 22, 2011

Baxter International Inc. (NYSE:BAX) and Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that they have entered into a global collaboration to develop and commercialize follow-on biologic products, also known as biosimilars.  Biosimilars replicate existing, branded biologics used in the treatment of a variety of diseases including cancer, autoimmune disorders and other chronic conditions.  With this collaboration, Baxter will leverage its leading clinical development and biologic manufacturing expertise, global leadership in sterile injectables and global commercial capabilities, while Momenta will provide its expertise in high-resolution analytics, characterization, and product and process development.... Read More

Dec 22, 2011

ADVATE for routine prophylaxis reduced annual bleed events in hemophilia A patients from forty-four to one as compared to an on-demand regimen in a clinical study... Read More

Dec 21, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 30th Annual J.P. Morgan Health Care Conference on Tuesday, January 10, 2012, at 2:30 p.m. (PT) or 5:30 p.m. (ET).... Read More

Dec 16, 2011

ADVATE for routine prophylaxis reduced annual bleed events in hemophilia A patients from forty-four to one as compared to an on-demand regimen in a clinical study... Read More

Dec 15, 2011

Baxter International Inc. (NYSE: BAX) demonstrated its commitment to volunteerism and product donation as well as to environmentally-conscious practices and corporate social responsibility through several recent initiatives and recognition. Baxter employees in the Asia Pacific region mobilized for a month of volunteering and giving back in their communities, and also responded quickly to the urgent need for peritoneal dialysis therapy and intravenous solutions in the aftermath of recent severe floods in Thailand. In addition, Baxter furthered its commitment to sustainable practices by building a new headquarters in Canada in accordance with Canadian Green Building Council LEED standards and was also recognized as a leader for the third year in the 2011 Green Rankings published by Newsweek magazine.... Read More

Dec 13, 2011

Baxter International Inc. (NYSE:BAX), and Synovis Life Technologies, Inc. (NASDAQ:SYNO) today announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures. The acquisition complements and will expand the portfolio of Baxter's regenerative medicine and biosurgery franchise, which includes a number of devices and biological products for hemostasis, tissue sealing and adherence.... Read More

Dec 13, 2011

Baxter International Inc. (NYSE:BAX), and Synovis Life Technologies, Inc. (NASDAQ:SYNO) today announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures. The acquisition complements and will expand the portfolio of Baxter's regenerative medicine and biosurgery franchise, which includes a number of devices and biological products for hemostasis, tissue sealing and adherence.... Read More

Nov 17, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011, at 12:00 p.m. (CT) or 1:00 p.m. (ET).... Read More

Nov 15, 2011

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.335 per Baxter common share, payable on January 4, 2012 to shareholders of record as of the close of business on December 9, 2011.  This represents an annual dividend rate of $1.34 per share, and an increase of approximately 8 percent over the previous annual rate of $1.24. ... Read More

Nov 10, 2011

Baxter International Inc. (NYSE:BAX) announced today that the company has completed its planned acquisition of Baxa Corporation, a privately held global company based in Englewood, Colo., for a cash consideration of $380 million.  Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery.... Read More

Nov 7, 2011

Baxter International Inc. (NYSE:BAX) today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI). The study evaluated efficacy and safety as well as the pharmacokinetics, infusion volumes, intervals, and rates compared to patients' previous intravenous immunoglobulin (IGIV) administration. Results from the study were presented on Saturday, Nov. 5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston.... Read More

Nov 4, 2011

Baxter International Inc. (NYSE:BAX) announced today the European launch of NUMETA (emulsion for infusion).  NUMETA was introduced at the 22nd Annual European Society of Pediatric and Neonatal Intensive Care (ESPNIC) Medical and Nursing Annual Congress in Hanover, Germany, as the first and only triple-chamber system with formulations specifically designed to meet the range of intravenous (IV) nutritional requirements of neonatal and pediatric patients (preterm newborns through age 18).  This premix therapy addresses an important unmet medical need to support neonatal and pediatric patients' changing daily nutritional needs with ready-to-use IV nutrition.... Read More

Nov 2, 2011

Results from an investigator-initiated study, which evaluated whether prophylactic use of FEIBA [Anti-inhibitor Coagulant Complex] can achieve a decrease in the frequency of joint and other bleeding events in patients with severe hemophilia A and inhibitors compared to on-demand therapy, were published today in The New England Journal of Medicine.  Patients with severe hemophilia A and inhibitors are at increased risk for serious bleeding complications.  Effective strategies to prevent bleeding in inhibitor patients have not yet been established.  Prophylaxis, where approved, is used to prevent a bleed and on-demand treatment is used only at the time of a bleeding episode.... Read More

Oct 26, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Credit Suisse 2011 Healthcare Conference on Wednesday, November 9, 2011, at 11:00 a.m. (CT) or 12:00 p.m. (ET).... Read More

Oct 20, 2011

Baxter International Inc. (NYSE:BAX) today reported third quarter net income of $576 million, an increase of 10 percent from $525 million reported in the third quarter of 2010.  Earnings per diluted share of $1.01 advanced 13 percent from $0.89 per diluted share reported in the prior-year period.  Baxter's third quarter financial results included an after-tax special charge of $48 million (or $0.08 per diluted share) for the resolution of long-standing litigation pertaining to average wholesale prices (AWP) and certain historical rebate and discount adjustments.  Baxter's third quarter 2010 financial results included an after-tax special item of $70 million (or $0.12 per diluted share) related to the impairment of assets associated with the divestiture of the U.S. multi-source generic injectables business.... Read More

Oct 14, 2011

Baxter International Inc. today announced initiation of a Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter's investigational recombinant von Willebrand factor (rVWF), for the treatment and prevention of bleeding episodes in patients with von Willebrand disease.  This condition is the most common type of inherited bleeding disorder, affecting both men and women, the majority of whom are undiagnosed due to mild symptoms.1 BAX 111 is the first recombinant von Willebrand product in clinical development.... Read More

Oct 6, 2011

The Honor Society of Nursing, Sigma Theta Tau International (STTI), is pleased to announce that Kathleen R. Stevens, EdD, MS, RN, ANEF, FAAN, will receive The Baxter International Foundation's 2011 Episteme Award in recognition of her multi-faceted  approach to evidence-based quality improvement that combines research, education and practice. An early leader in her field, Dr. Stevens moves research into practice through community engagement, academic practice partnership and clinical effectiveness to improve patient care.... Read More

Oct 3, 2011

Baxter International Inc. (NYSE: BAX) continued to advance math and science education and reduce its environmental footprint through several recent initiatives. Baxter also supported the opening of a new education center in Chicago to prepare high schoolers for careers in health sciences and optimized product transport in Europe. The company was also recognized for the 10th year as Medical Products leader in the Dow Jones Sustainability Index.... Read More

Sep 30, 2011

Recent safety concerns in the preparation and delivery of parenteral nutrition (PN), commonly referred to as intravenous (IV) nutrition, prompted leaders from several major organizations to participate in a PN Safety Summit on September 23, 2011.  The Summit participants agreed to several recommendations that will improve the safety of PN therapy and patient care, in the areas of PN order prescribing, order review and verification, and formulation compounding.... Read More

Sep 30, 2011

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies (PI).... Read More

Sep 29, 2011

Recent safety concerns in the preparation and delivery of parenteral nutrition (PN), commonly referred to as intravenous (IV) nutrition, prompted leaders from several major organizations to participate in a PN Safety Summit on September 23, 2011.  The Summit participants agreed to several recommendations that will improve the safety of PN therapy and patient care, in the areas of PN order prescribing, order review and verification, and formulation compounding.... Read More

Sep 21, 2011

DEERFIELD, Ill. (September 20, 2011) Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its third quarter 2011 financial results on Thursday, October 20, 2... Read More

Aug 31, 2011

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has expanded the indication of  ARTISS [Fibrin Sealant (Human)] to include adhering tissue flaps during facial rhytidectomy surgery (face-lift).  ARTISS is the only premixed, ready-to-use fibrin sealant specifically indicated for tissue adherence in facial rhytidectomy (face-lift) and burn surgeries. It was first approved by the FDA in 2008 to adhere autologous skin grafts to surgically prepared wound beds resulting from burns in adult and pediatric populations one year of age or older.... Read More

Aug 30, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 21, at 7:30 a.m. (CT) or 8:30 a.m. (ET).... Read More

Aug 25, 2011

The transaction includes a total upfront cash consideration of $380 million and is expected to close following satisfaction of customary closing conditions and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.  Annual sales for Baxa were approximately $150 million in 2010, and Baxter expects the future top-line growth of this business to be accretive to the company's future sales growth.  In addition, Baxter expects this transaction to be neutral to full-year 2012 earnings excluding dilution of approximately $0.03 to $0.05 per diluted share related to acquisition accounting and transaction-related expenses, and increasingly accretive thereafter.... Read More

Aug 22, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, at 12:00 p.m. (CT) or 1:00 p.m. (ET).... Read More

Jul 28, 2011

Baxter International Inc. (NYSE:BAX) announced today that it has established Baxter Ventures to invest up to $200 million in equity in promising early-stage companies developing therapies that complement Baxter's existing portfolio.... Read More

Jul 26, 2011

Baxter International Inc. (NYSE: BAX) announced today that new data from a series of studies on BAX 499, an investigational compound for potential subcutaneous hemophilia therapy, were presented this week during the 23rd annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.  BAX 499 is in early stage clinical development to treat blood clotting disorders hemophilia A and B by targeting a novel pathway responsible for regulating the clotting process.  The studies presented at ISTH validate the pathway as a potentially viable target for the treatment of hemophilia. ... Read More

Jul 26, 2011

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.31 per Baxter common share. ... Read More

Jul 25, 2011

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency (PI).  The approval of this new route of administration will allow physicians and PI patients to work together to determine which route of administration of GAMMAGARD LIQUID is most appropriate. Subcutaneous use of GAMMAGARD LIQUID allows patients to self-administer their therapy at home on a weekly basis. ... Read More

Jul 21, 2011

Baxter International Inc. (NYSE:BAX) today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011. ... Read More

Jul 8, 2011

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI). The subcutaneous administration is facilitated by recombinant human hyaluronidase, an enzyme that increases dispersion and absorption of the IG. The data confirm the interim results presented late in 2010 and support the recent submission of a biologics license application to the United States Food and Drug Administration. ... Read More

Jul 7, 2011

New research published online today in Circulation Research found that injections of adult patients' own CD34+ stem cells reduced reports of angina episodes and improved exercise tolerance time in patients with chronic, severe refractory angina (severe chest discomfort that did not respond to other therapeutic options).... Read More

Jun 30, 2011

Baxter International Inc. (NYSE: BAX) today released its 2010 Sustainability Report, marking the 12th consecutive year the company has released a report about its social, economic and environmental performance. The report features progress toward the company's sustainability priorities and goals and its commitment to addressing global sustainability challenges through a range of initiatives.... Read More

Jun 24, 2011

Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.  With adoption by the European Commission, Baxter will receive marketing authorization for KIOVIG MMN indication in all European Union (EU) Member States- the first centrally-licensed indication for an immunoglobulin preparation for MMN.... Read More

Jun 20, 2011

DEERFIELD, Ill. - (June 20, 2011)-Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its second quarter 2011 financial results on Thursday, July 21, 2011, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).  To access the call, please dial 866-261-7280 (domestic) or 703-639-1228 (international).  Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. ... Read More

Jun 13, 2011

Baxter International Inc. (NYSE:BAX) announced today at the American Society of Health-System Pharmacists Summer Meeting and Exhibition that it has launched NEXTERONE® (amiodarone HCl) Premixed Injection, the first and only ready-to-use premixed intravenous (IV) bag version of the antiarrhythmic agent amiodarone in the United States. ... Read More

Jun 8, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, at 9:20 a.m. (PT) or 11:20 a.m. (CT).... Read More

May 26, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the William Blair & Company 31st Annual Growth Stock Conference on Tuesday, June 14, at 8:50 a.m. (CT) or 9:50 a.m. (ET).... Read More

May 18, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Wednesday, June 8, at 9:20 a.m. (PT) or 11:20 a.m. (CT).... Read More

May 4, 2011

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Deutsche Bank Securities Inc. 36th Annual Health Care Conference on Wednesday, May 4, at 9:20 a.m. (ET) or 8:20 a.m. (CT).... Read More

May 2, 2011

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.31 per Baxter common share. ... Read More

Apr 28, 2011

In recognition of his significant contributions to the field of health services research, Edward H. Wagner, MD, MPH, has been named the 2011 recipient of the William B. Graham Prize for Health Services Research. The Prize, funded by The Baxter International Foundation and managed by the Association of University Programs in Health Administration (AUPHA), will be awarded on June 25, 2011, at the AUPHA Annual Meeting in Charleston, S.C.... Read More

Apr 21, 2011

Baxter International Inc. (NYSE:BAX) today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011. ... Read More

Apr 18, 2011

Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to acquire privately-held Prism Pharmaceuticals, Inc., a specialty pharmaceutical company based in King of Prussia, PA.  Prism Pharmaceuticals has developed and received U.S. Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE® (amiodarone HCl), an antiarrhythmic agent.  The NEXTERONE product portfolio, which does not contain polysorbate 80 or benzyl alcohol, includes the first and only ready-to-use premixed intravenous (IV) bag formulations as well as vials and a pre-filled syringe.... Read More

Apr 18, 2011

Baxter International Inc. (NYSE: BAX) announced today the results of a phase III study evaluating the safety and efficacy of ARTISS [Fibrin Sealant (Human)] in 75 patients. The study compared the total drainage volume for each side of the face at 24 hours post rhytidectomy, or face lift surgery. This data was presented at the American Association of Plastic Surgeons (AAPS) 90th Annual Meeting on April 10 in Boca Raton, Fla.... Read More

Apr 11, 2011

Baxter International Inc. (NYSE: BAX) announced today the results of a phase III study evaluating the safety and efficacy of ARTISS [Fibrin Sealant (Human)] in 75 patients. The study compared the total drainage volume for each side of the face at 24 hours post rhytidectomy, or face lift surgery. This data was presented at the American Association of Plastic Surgeons (AAPS) 90th Annual Meeting on April 10 in Boca Raton, Fla.... Read More

Mar 29, 2011

Baxter International Inc. and The Baxter International Foundation, the philanthropic arm of Baxter, today announced their combined 2010 charitable giving of nearly $80 million, including support of math and science education. The company was also recently recognized by the U.S. Customs-Trade Partnership Against Terrorism program, U.S. Environmental Protection Agency's SmartWay® and Fortune 500 Green Power Challenge programs, as well as on the Global 100 Most Sustainable Corporations and 100 Best Corporate Citizens lists.... Read More

Mar 24, 2011

Baxter International (NYSE:BAX), will host a quarterly conference call to discuss its first quarter 2011 financial results on Thursday, April 21, 2011, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time).  To access the call, please dial 866-261-7280 (domestic) or 703-639-1228 (international).  Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. ... Read More

Mar 23, 2011

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.  As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. ... Read More

Mar 17, 2011

(BUSINESS WIRE) - Baxter International Inc. (NYSE:  BAX) announced today that it will present at the Barclay's Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 8:00 a.m. (ET) or 7:00 a.m. (CT).... Read More

Mar 2, 2011

PREFLUCEL, a seasonal vaccine composed of purified, inactivated split influenza virions, is the result of dedicated product development efforts to provide a well-tolerated and effective innovative vaccine that can be dependably manufactured for each influenza season.  PREFLUCEL is manufactured using Vero cell technology, Baxter's proprietary technology platform, offering an innovative method of vaccine production compared to conventional embryonated chicken egg production, which has been used for decades. It is indicated for prophylaxis of influenza in adults older than 18 years and elderly populations. ... Read More

Feb 23, 2011

Baxter International Inc. (NYSE: BAX) announced today that it will present at the 2011 RBC Capital Markets' Healthcare Conference on Thursday, March 3, 2011 at 9:30 a.m. (ET) or 8:30 a.m. (CT).... Read More

Feb 15, 2011

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.31 per Baxter common share. ... Read More

Feb 15, 2011

Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has elected two new corporate officers of the company.... Read More

Jan 31, 2011

Baxter International Inc. (NYSE:BAX) today announced the launch of OLIMEL (Amino Acids, Dextrose and Lipids, with/without Electrolytes) emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's (A.S.P.E.N.) Clinical Nutrition Week.  OLIMEL is the country's first triple-chamber bag for parenteral nutrition (PN) and provides adult patients with the essential ingredients of balanced nutrition: protein, carbohydrates and lipids (fats), in a single container, simplifying the preparation of PN for hospitalized patients.... Read More

Jan 13, 2011

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Allegiance Health in Jackson, Mich., is the recipient of the 2010 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 13, 2011

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Allegiance Health in Jackson, Mich., is the recipient of the 2010 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 13, 2011

In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Allegiance Health in Jackson, Mich., is the recipient of the 2010 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Dec 15, 2010

Baxter International Inc.'s (NYSE: BAX) Science@Work education program recently hosted interactive science workshops by Baxter scientists to help Chicago-area high school students experience the science behind healthcare careers. The company also announced product donations to support relief efforts for the Haiti cholera outbreak, and was recognized by leading sustainability rankings including Newsweek magazine's "Green Rankings" and the Maplecroft Climate Innovation Indexes. Further information about Baxter's sustainability activities can be found at http://sustainability.baxter.com/.... Read More

Dec 13, 2010

Baxter International Inc. (NYSE:BAX) announced today that its Board of Directors has approved a share repurchase authorization of up to $2.5 billion of the company's common stock.  ... Read More

Dec 10, 2010

People with alpha1- antitrypsin deficiency (AATD) have reduced levels of a naturally occurring blood protein that protects the lungs.  The condition can result in early onset emphysema.  It has been estimated that less than 10 percent of people living with AATD in the United States have been properly diagnosed1.  Baxter offers a test kit to encourage testing for this hereditary disease.... Read More

Dec 9, 2010

Baxter's long-standing relationships with global humanitarian aid organizations AmeriCares and Direct Relief International have helped to facilitate timely, targeted support to help address the recent cholera outbreak in central Haiti. Collaboration with these organizations has yielded shipments of hundreds of thousands of intravenous solutions, including lactated ringers and dextrose, and sets used to administer the solutions to help meet the hydration needs of people affected by waterborne bacteria, which can spread through contaminated water. Baxter will continue to work with these donor partners to assess the ongoing relief needs in Haiti. ... Read More

Dec 8, 2010

Baxter's long-standing relationships with global humanitarian aid organizations AmeriCares and Direct Relief International have helped to facilitate timely, targeted support to help address the recent cholera outbreak in central Haiti. Collaboration with these organizations has yielded shipments of hundreds of thousands of intravenous solutions, including lactated ringers and dextrose, and sets used to administer the solutions to help meet the hydration needs of people affected by waterborne bacteria, which can spread through contaminated water. Baxter will continue to work with these donor partners to assess the ongoing relief needs in Haiti. ... Read More

Dec 7, 2010

The effect of cost constraints and new legislation on healthcare innovation was the topic of a keynote address by Bob Parkinson at the 11th annual Business of Healthcare Conference at Northwestern University's Kellogg School of Management.  The conference was attended by approximately 200 students, alumni, faculty and industry professionals, who participated in six panel discussions exploring the importance of innovation in healthcare. Excerpts from his talk can be viewed here.... Read More

Dec 6, 2010

ORLANDO, Fla., December 6, 2010 -- Recombinant von Willebrand factor (rVWF) may be safe and well tolerated in patients with type 3 and severe type 1 von Willebrand disease, according to interim data from a Phase 1 multicenter, international clinical study presented today at the 52nd Annual Meeting of the American Society of Hematology.1 The interim data from 22 patients in the 32-patient study also suggest rVWF has a pharmacokinetic profile that is comparable to plasma-derived von Willebrand factor (pdVWF),1 the current standard for treatment for patients with the disease. The condition is associated with prolonged bleeding times, and the resulting complications can, in some cases, be considered life-threatening.2... Read More

Dec 6, 2010

Baxter International Inc. (Headquarters: Illinois, USA) ("Baxter") and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan) ("Takeda") today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market. Specifically:... Read More

Dec 3, 2010

People with alpha1- antitrypsin deficiency (AATD) have reduced levels of a naturally occurring blood protein that protects the lungs.  The condition can result in early onset emphysema.  It has been estimated that less than 10 percent of people living with AATD in the United States have been properly diagnosed1.  Baxter offers a test kit to encourage testing for this hereditary disease.... Read More

Dec 2, 2010

Baxter International Inc. (Headquarters: Illinois, USA) ("Baxter") and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan) ("Takeda") today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market. Specifically:... Read More

Nov 24, 2010

Baxter's long-standing relationships with global humanitarian aid organizations AmeriCares and Direct Relief International have helped to facilitate timely, targeted support to help address the recent cholera outbreak in central Haiti. Collaboration with these organizations has yielded shipments of hundreds of thousands of intravenous solutions, including lactated ringers and dextrose, and sets used to administer the solutions to help meet the hydration needs of people affected by waterborne bacteria, which can spread through contaminated water. Baxter will continue to work with these donor partners to assess the ongoing relief needs in Haiti.... Read More

Nov 19, 2010

DEERFIELD, Ill., November 19, 2010 -   Baxter International Inc. (NYSE:  BAX) announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets. ... Read More

Nov 18, 2010

Baxter International Inc. (NYSE:BAX) announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application for a Home Hemodialysis (HD) system in development through a collaboration between DEKA Research and Development Corp., HHD LLC, and Baxter.  The IDE approval allows the companies to initiate a clinical study in patients undergoing hemodialysis treatment.... Read More

Nov 17, 2010

Dayna Fladhammer is the mother of three children - Charlie, Kate and Tommy - who have Primary Immunodeficiency (PI), a disorder in which patients lack one or more types of immune proteins or cells that protect their bodies from germs like bacteria or viruses. Last year, Dayna worked with Baxter Healthcare Corporation's BioScience business to develop a therapeutic play kit and doll, Igi V. (pronounced "Ig-e-vee"), to help young PI patients better understand the antibody-replacement therapy - Immune Globulin Intravenous (IGIV) - they receive to bolster their immune systems. The play kit was a success with patients and families throughout the United States, and the doll is now available throughout Europe.... Read More

Nov 16, 2010

Dayna Fladhammer is the mother of three children - Charlie, Kate and Tommy - who have Primary Immunodeficiency (PI), a disorder in which patients lack one or more types of immune proteins or cells that protect their bodies from germs like bacteria or viruses. Last year, Dayna worked with Baxter Healthcare Corporation's BioScience business to develop a therapeutic play kit and doll, Igi V. (pronounced "Ig-e-vee"), to help young PI patients better understand the antibody-replacement therapy - Immune Globulin Intravenous (IGIV) - they receive to bolster their immune systems. The play kit was a success with patients and families throughout the United States, and the doll is now available throughout Europe.... Read More

Nov 11, 2010

Dayna Fladhammer is the mother of three children - Charlie, Kate and Tommy - who have Primary Immunodeficiency (PI), a disorder in which patients lack one or more types of immune proteins or cells that protect their bodies from germs like bacteria or viruses. Last year, Dayna worked with Baxter Healthcare Corporation's BioScience business to develop a therapeutic play kit and doll, Igi V. (pronounced "Ig-e-vee"), to help young PI patients better understand the antibody-replacement therapy - Immune Globulin Intravenous (IGIV) - they receive to bolster their immune systems. The play kit was a success with patients and families throughout the United States, and the doll is now available throughout Europe.... Read More

Nov 9, 2010

Baxter continues to generate strong cash flow and has returned significant value to shareholders in the form of dividends and share repurchases.  Since the beginning of 2010, Baxter has returned approximately $2.0 billion to shareholders through dividends totaling $688 million and share repurchases of approximately $1.3 billion (or 26 million shares).... Read More

Oct 29, 2010

Baxter International Inc. (NYSE:BAX) announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC (LSE:HIK). The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments. The sale of this business will allow Baxter to redirect resources toward its proprietary, enhanced packaging offerings and formulation technologies, consistent with the company's focus on product differentiation.  Baxter expects to record an after-tax special charge in the third quarter of approximately $70 million (or $0.12 per diluted share), principally to write down the assets of the business.... Read More

Oct 25, 2010

Baxter ranked first in the healthcare category of Newsweek magazine's second annual "Green Rankings" list of the 500 largest publicly traded companies in America measured by revenue, market capitalization and number of employees. Baxter ranked #15 in the overall list.... Read More

Oct 25, 2010

Baxter International Inc. (NYSE: BAX) today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.... Read More

Oct 21, 2010

Baxter International Inc. (NYSE:BAX) today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.... Read More

Oct 18, 2010

For the second year, Baxter has been named among the top performers in climate-related innovation and carbon management in the United States by the Maplecroft Climate Innovation Indexes (CII), created in collaboration with Bloomberg.... Read More

Oct 12, 2010

DEERFIELD, Ill., October 12, 2010 -- Baxter International Inc. (NYSE:BAX) announced the formation of a new Medical Products business, combining the company's Renal and Medication Delivery businesses into a single global business unit. This new business brings together two organizations that can leverage many capabilities and requirements across product development, supply chain, manufacturing and regulatory affairs.... Read More

Oct 11, 2010

Baxter was recently recognized for its vision and focus on social responsibility and commitment to its culture and employees in receiving the 2010 Trailblazer Best Medical Device Company of the Year award from PM360, a pharmaceutical and medical device industry publication.  The awards honor outstanding achievement and innovation in pharmaceutical/biotech and medical device marketing. ... Read More

Oct 6, 2010

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey.  HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.... Read More

Sep 29, 2010

Baxter International Inc. (NYSE:BAX) today announced the first approval of PREFLUCEL by the Austrian Agency for Health and Food Safety (AGES).  The vaccine was shown to be effective in preventing seasonal influenza and is indicated for prophylaxis of influenza in adults and the elderly.  PREFLUCEL is manufactured using Baxter's proprietary advanced Vero cell technology.... Read More

Sep 27, 2010

Strategic shipments made in the spring of 2010 and valued at more than $9 million positioned donor partners, AmeriCares and Direct Relief International, to pull from inventory and provide products valued at approximately $70,000 in support of the flood relief efforts in Pakistan and India.... Read More

Sep 16, 2010

Baxter International Inc.'s (NYSE: BAX) Science@Work education initiative achieved a milestone with the opening of Instituto Health Sciences Career Academy (IHSCA), a new Chicago high school dedicated to preparing students for healthcare careers. The school will focus on providing Latinos with education and preparation to pursue careers that meet the nation's healthcare needs. Baxter also continued its commitment to sustainable product design with the introduction of a new dialyzer, and was named 2010 Medical Products Industry Leader of the Dow Jones Sustainability Index for the ninth year.... Read More

Aug 31, 2010

Baxter will work with Halozyme on potential regulatory and commercial paths forward, including presenting information to the U.S. Food and Drug Administration.... Read More

Aug 24, 2010

"The agreement with Kamada underscores Baxter's commitment to expanding the diagnosis of alpha1 -antitrypsin deficiency by bringing new and innovative therapeutic options to Alpha-1 patients and their treating physicians," said Larry Guiheen, president of Global BioPharmaceuticals, Baxter BioScience.... Read More

Aug 11, 2010

More than 40 million Americans lack adequate health insurance. This includes an estimated 1.3 million in the Chicago area, where Baxter International Inc. is headquartered. As a leading healthcare company, Baxter is committed to increasing access to healthcare around the world through both its business and its community efforts, particularly in areas where Baxter employees live and work.... Read More

Jul 27, 2010

The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.29 per share of Baxter common stock. ... Read More

Jul 22, 2010

Baxter International Inc. (NYSE:BAX) today announced its financial results for the second quarter of 2010, reporting earnings in line with the company's previously issued guidance of $0.90 to $0.93 per diluted share. ... Read More

Jul 15, 2010

Baxter established roots in Belgium in the mid-1950s, when it became the first company in Belgium to commercially manufacture sterile intravenous solutions.  Today, Baxter remains a leader in Belgium in providing products that save and sustain lives.  Belgium also continues to be a strategic location for Baxter manufacturing and research and development (R&D) in Europe.... Read More

Jul 13, 2010

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued its final order regarding the previously communicated recall of COLLEAGUE infusion pumps from the U.S. market.  Baxter will offer replacement infusion pumps or refunds to owners of COLLEAGUE pumps and will execute the recall over the next two years to minimize disruption to patient care.... Read More

Jul 13, 2010

Baxter International Inc. (NYSE: BAX) today announced final E.U./U.S. post-authorization safety surveillance (PASS) data that support the safety and efficacy profile of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] previously documented in prospective clinical trials in a new study published in the journal Haemophilia.1  Similar safety, inhibitor profile and efficacy were seen in previously treated patients (PTPs) with severe to moderately severe hemophilia A as well as across a broad range of hemophilia patients in everyday practice.  The results are from the large, prospective, open-label, observational study examining 521 patients of any age and with severe to moderately severe  hemophilia A who were treated prophylactically (preventatively) or on-demand (as needed) with ADVATE therapy at the discretion of the participating physicians in the United States and 11 countries in the European Union.... Read More

Jul 12, 2010

BUENOS AIRES, ARGENTINA (July 12, 2010) - Baxter International Inc., in its continued support of the World Federation of Hemophilia (WFH), today announced the launch of the "Our Lives with Hemophilia:  The Stories of Vaibhav and Paul" video podcast at the Hemophilia 2010 World Congress of the WFH.  The video podcast provides perspective into the daily lives of two young men with severe hemophilia A from diverse backgrounds.  It is the final episode in the Achieving Treatment for All:  Hemophilia and Bleeding Disorders Educational Series, developed to spur a global dialogue and action around the need for broad-based access to care and treatment for people with hemophilia and other inherited bleeding disorders. ... Read More

Jul 7, 2010

Baxter India observed World Hemophilia Day in collaboration with eight healthcare facilities across the country in cities including Mumbai, Chennai, Kolkata, Lucknow, Delhi, Trivandrum and Jaipur. Activities ranged from Continuing Medical Education (CME) for doctors, camps for patients, as well as patient and doctor meetings with the purpose of increasing knowledge and management of hemophilia. Over 1,200 patients and their families along with 170 doctors participated in these activities all over the country.... Read More

Jul 7, 2010

For five years, Jim McFarlin hoped his kidneys would get better by themselves.  That's how long he went before seeing a nephrologist, (kidney specialist) after a checkup in 2001 revealed high levels of protein in his urine and creatinine (waste generated from muscle cells) in his system.  Both are indicators of compromised kidney function.... Read More

Jun 25, 2010

For five years, Jim McFarlin hoped his kidneys would get better by themselves.  That's how long he went before seeing a nephrologist, (kidney specialist) after a checkup in 2001 revealed high levels of protein in his urine and creatinine (waste generated from muscle cells) in his system.  Both are indicators of compromised kidney function.... Read More

Jun 24, 2010

Baxter International Inc. (NYSE: BAX) today released its 2009 Sustainability Report - Our Priorities for a More Sustainable Future, marking the 11th consecutive year the company has released a sustainability report about its social, economic and environmental performance. The report features progress the company has made toward its sustainability priorities and goals, and its commitment to addressing global sustainability challenges through a range of initiatives, including advancing product stewardship through product carbon footprint certification and engaging employees in volunteer initiatives in their communities.... Read More

Jun 18, 2010

In observance of World Hemophilia Day on April 17th, Baxter Healthcare Corporation Taiwan reaffirmed Baxter's ongoing commitment to optimizing hemophilia care and improving the lives of people with hemophilia by hosting the closing ceremony of the first "Patients without Borders Training Camp".  The celebration included representatives from the Hematology Society of Taiwan, Hemophiliacs' Rights Taiwan and the distinguished guest Dr. Chien Shin-Nan, a hematologist from the Hemophilia Care & Research Center at Tri-Service General Hospital.  Approximately 60 patients and their families participated in the celebration with Baxter employees from around the globe. The "Patients without Borders Training Camp" is designed to help hemophilia patients contribute back to society in various ways. Participants are equipped with the skills, knowledge and communication tools needed to increase their social engagement and educate others about hemophilia and the misperceptions of bleeding disorders.... Read More

Jun 17, 2010

Braine-l'Alleud, Belgium, 17 June, 2010 - Baxter today moved its Research & Development facility, including commercial and administrative offices, to Parc de l'Alliance (Alliance Park), Braine l'Alleud, based south of Brussels, Belgium.  One of three Research & Development facilities in Europe, Alliance Park represents a major milestone for Baxter operations in Belgium, and strengthens the company's capacity to continue developing leading-edge technologies and products. ... Read More

Jun 16, 2010

In observance of World Hemophilia Day on April 17th, Baxter Healthcare Corporation Taiwan reaffirmed Baxter's ongoing commitment to optimizing hemophilia care and improving the lives of people with hemophilia by hosting the closing ceremony of the first "Patients without Borders Training Camp".  The celebration included representatives from the Hematology Society of Taiwan, Hemophiliacs' Rights Taiwan and the distinguished guest Dr. Chien Shin-Nan, a hematologist from the Hemophilia Care & Research Center at Tri-Service General Hospital.  Approximately 60 patients and their families participated in the celebration with Baxter employees from around the globe. The "Patients without Borders Training Camp" is designed to help hemophilia patients contribute back to society in various ways. Participants are equipped with the skills, knowledge and communication tools needed to increase their social engagement and educate others about hemophilia and the misperceptions of bleeding disorders.... Read More

Jun 4, 2010

Baxter employees worldwide sponsored events that promote earth-friendly activities and sustainable living while encouraging employees to learn more about the many ways to support Baxter's commitment to creating a more sustainable world during the company's second annual Baxter World Environment Week. The global event, held the first week of June, corresponds with the United Nation's World Environment Day, and demonstrates the integration of sustainability into Baxter's culture and how the company's collective efforts can make a positive impact on local and global communities.... Read More

Jun 1, 2010

DEERFIELD, Ill., June 1, 2010 -- Baxter International Inc. (NYSE:BAX) announced today two executive changes.  Robert M. Davis, has been appointed corporate vice president and president of Baxter's Renal business, filling a role vacated by Bruce H. McGillivray, who is retiring after 30 years of service to the company.... Read More

May 20, 2010

DEERFIELD, Ill., May 17, 2010 -- Baxter International Inc. (NYSE:BAX) announced today that a voluntary recall of all manufactured lots of HYLENEX recombinant (hyaluronidase human injection) has been initiated as a precautionary measure due to instances of particulate matter observed in a limited number of HYLENEX vials during routine stability testing.  Baxter is working with the product's NDA-holder, Halozyme Therapeutics, to investigate the root cause of the issue and appropriately address the situation.... Read More

May 20, 2010

ARLINGTON, Va. and DEERFIELD, Ill., May 20, 2010 - In recognition of his contributions to the field of health services research and lifelong achievements, Uwe E. Reinhardt, Ph.D., has been named the 2010 recipient of the William B. Graham Prize for Health Services Research. The Prize, funded by T... Read More

May 17, 2010

DEERFIELD, Ill., May 17, 2010 -- Baxter International Inc. (NYSE:BAX) announced today that a voluntary recall of all manufactured lots of HYLENEX recombinant (hyaluronidase human injection) has been initiated as a precautionary measure due to instances of particulate matter observed in a limited number of HYLENEX vials during routine stability testing.  Baxter is working with the product's NDA-holder, Halozyme Therapeutics, to investigate the root cause of the issue and appropriately address the situation.... Read More

May 14, 2010

Baxter's product donations, grants and employee financial giving and volunteerism help address critical local and global needs. In 2009, combined contributions from Baxter and The Baxter International Foundation, the philanthropic arm of Baxter, totaled more than $52 million, and employees recorded 159,000 hours volunteering within their communities. These funds and employees' time are used in a variety of ways to support organizations that are the most relevant and will have the highest impact on the community.... Read More

May 4, 2010

The Board of Directors of Baxter International Inc. (NYSE:BAX) today announced a quarterly dividend and the results of votes taken at the company's Annual Meeting of Shareholders held earlier today.... Read More

May 3, 2010

Baxter Healthcare Corporation today announced that it will recall COLLEAGUE infusion pumps from the U.S. market pursuant to an order under its existing June 2006 consent decree with the U.S. Food and Drug Administration (FDA).   Baxter will work with the FDA to ensure that the recall process provides customers appropriate alternatives for supporting patients' needs.... Read More

May 3, 2010

Baxter Healthcare Corporation today announced that it will recall COLLEAGUE infusion pumps from the U.S. market pursuant to an order under its existing consent decree with the U.S. Food and Drug Administration (FDA).   Baxter will work with the FDA to ensure that the recall process provides customers appropriate alternatives for supporting patients' needs.... Read More

Apr 29, 2010

Today, Baxter International, Inc. and the Jeffrey Modell Foundation (JMF) are supporting expanded global activities in conjunction with the 6th annual World Day of Immunology. The goal is to help increase awareness for earlier diagnosis and treatment of Primary Immunodeficiency Diseases (PID), a group of genetic disorders that occur when part of the immune system is missing or does not work correctly.... Read More

Apr 28, 2010

Next week, Chicago will host the 2010 Biotechnology Industry Organization (BIO) International Convention, where an estimated 15,000 global industry leaders will come together to address many of the most pressing health, food and energy challenges facing our world today.... Read More

Apr 26, 2010

 ... Read More

Apr 26, 2010

BioPharma Solutions (BPS), Baxter's contract manufacturing business, was named "Best Contract Manufacturing Organization" at the third annual Vaccine Industry Excellence (ViE) Awards, announced on April 20, 2010, at the World Vaccine Congress in Washington, D.C.   This is the first time Baxter has received this award, which is a testament to the company's commitment to excellence in contract manufacturing and customer service.... Read More

Apr 26, 2010

If you learned that you were ill, chances are good that you would want to know as much as you could about your treatment options.  You would likely want to understand which option was best for your health, and for your lifestyle. ... Read More

Apr 23, 2010

If you learned that you were ill, chances are good that you would want to know as much as you could about your treatment options.  You would likely want to understand which option was best for your health, and for your lifestyle. ... Read More

Apr 23, 2010

 ... Read More

Apr 22, 2010

DEERFIELD, Ill., April 22, 2010 – Baxter International Inc. (NYSE:BAX) today reported first quarter net income of $525 million, an increase of 2 percent from $516 million reported in the first quarter of 2009. Earnings per diluted share of $0.86 increased 4 percent from $0.83 per diluted share reported in the prior-year period. Baxter's first quarter financial results included a one-time, non-cash special charge of $39 million (or $0.07 per diluted share) related to a change in the tax treatment of post-retirement prescription drug benefits under recent U.S. healthcare reform legislation.... Read More

Apr 21, 2010

Baxter International Inc. (NYSE:BAX) today announced strong financial results for the first quarter of 2011, and raised its outlook for full-year 2011. ... Read More

Apr 17, 2010

Held each year on April 17, World Hemophilia Day serves as an opportunity for the “many faces of bleeding disorders” – patients, caregivers, healthcare professionals, advocacy groups, governments and industry partners around the world – to unite to raise awareness of these serious conditions and their impact. In observance of World Hemophilia Day 2010, Baxter reaffirmed its ongoing commitment to optimizing hemophilia care and improving the lives of people living with hemophilia worldwide by supporting access through community participation, ensuring patient access to appropriate therapies and advancing new treatments that may improve patient outcomes.... Read More

Apr 14, 2010

DEERFIELD, Ill., April 14, 2010 – In observance of World Hemophilia Day, Baxter International Inc. today reaffirmed its ongoing commitment to optimizing hemophilia care and improving the lives of people with hemophilia worldwide. With proper care and treatment, people with bleeding disorders can live longer, more fulfilling lives than ever before, but tragically, 75 percent of people with bleeding disorders do not receive adequate treatment, and significant disparities in care exist between developed and developing countries.1, 2 To help address these disparities, Baxter, in its continued work with the World Federation of Hemophilia (WFH), today made available “The Many Faces of Bleeding Disorders – United to Achieve Treatment for All” educational video podcast (available at www.wfh.org/whd) and reaffirmed its support for WFH and humanitarian aid partner, AmeriCares, to provide therapies for people living with hemophilia who are most in need.... Read More

Apr 13, 2010

TORONTO, April 13, 2010 – Baxter International Inc. (NYSE: BAX) and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer’s disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.... Read More

Apr 7, 2010

DEERFIELD, IL – April 7, 2010 — Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick – pointing to a greater need for awareness and education around the condition and its treatment.... Read More

Apr 6, 2010

Deerfield, Ill., April 6, 2010 — Baxter International Inc. (NYSE: BAX) and Nycomed today announced the U.S. Food and Drug Administration (FDA) approval of TachoSil (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only adjunctive hemostatic agent available in the U.S. that combines a collagen patch with a coating of human coagulation factors. This ready-to-use patch can be applied directly to the bleeding area either dry or wet. In the presence of saline, blood or other bodily fluids, the coagulation factors dissolve to form a fibrin clot, which adheres the TachoSil patch to the bleeding surface and achieves hemostasis.... Read More

Apr 6, 2010

DEERFIELD, IL – April 6, 2010 — Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick – pointing to a greater need for awareness and education around the condition and its treatment.... Read More

Mar 31, 2010

In 2008, Baxter launched Science@Work: Expanding Minds with Real-World Science in partnership with Chicago Public Schools (CPS), Renaissance Schools Fund (RSF) and the Illinois Institute of Technology (IIT), as a five-year, three-part program aimed at providing enhanced biotechnology science education opportunities for CPS students and teachers. Science@Work represents the first ever contribution to biotechnology education in CPS history, and includes the adoption of Lindblom Math & Science Academy in Englewood, opening two new schools in downtown Chicago, providing teacher training and furnishing needed materials for schools. As part of Science@Work, three Baxter scientists --Dr. Francisco Rausa, Ph.D., Barrett Rabinow, Ph.D. and Delara Motlagh, Ph.D. -- recently shared their expertise with more than 220 Chicago Public School science teachers from 35 schools throughout the district – bringing science to life for nearly 31,000 students.... Read More

Mar 30, 2010

DEERFIELD, IL – March 25, 2010 – Dehydration is a condition that can have a significant impact on children and, if left untreated, may lead to serious complications and hospitalization. A national survey of more than 800 parents with children between the ages of one month and 10 years found that three out of five parents reported needing to know more information about dehydration, such as when to see a physician, warning signs, and treatment, if their child became sick – pointing to a greater need for awareness and education around the condition and its treatment.... Read More

Mar 18, 2010

DEERFIELD, Ill., March 18, 2010 – Baxter International Inc., its employees and The Baxter International Foundation are committed to supporting global and local communities through financial contributions; product donations; employee volunteerism, including support of education; and other initiatives. In 2009, charitable giving exceeded $52 million to address critical needs locally and globally.... Read More

Mar 11, 2010

DEERFIELD, Ill., March 11, 2010 – Baxter International Inc. (NYSE:BAX), in conjunction with DynPort Vaccine Company LLC (DVC), a CSC Company (NYSE:CSC), today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine. PREFLUCEL is made using Baxter's Vero cell culture platform and does not contain an adjuvant or preservatives. The data were presented at the International Congress on Infectious Disease (ICID) in Miami, Florida.... Read More

Mar 11, 2010

DEERFIELD, Ill., March 11, 2010 – As the incidence of diabetes and hypertension continues to grow worldwide – and increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems – the need for early patient education about kidney disease and treatment options, including home-based treatments, has become critical.... Read More

Mar 10, 2010

In November 2009, 59-year-old Jean Louis Clemendot set out to do something no one else with end-stage kidney disease had ever done: sail solo across the Atlantic Ocean, from the Canary Islands off the northwest coast of Africa, to the Caribbean island of Martinique. The journey would require three to four weeks at sea – a daunting task for anyone, but particularly for someone with kidney failure, who relies on dialysis to cleanse the blood of waste products normally removed by healthy kidneys.... Read More

Mar 2, 2010

DEERFIELD, Ill., March 2, 2010 – Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has classified Baxter’s recent Urgent Product Recall regarding Increased Intraperitoneal Volume (IIPV), or overfill of the abdominal cavity, associated with HomeChoice and HomeChoice Pro peritoneal dialysis cyclers as a Class I recall. This action has been classified as a Class I recall because of the risk of serious injury or patient death that could be associated with the use of this device. Over the last two years, Baxter has received serious injury reports and at least one patient death report associated with this issue.... Read More

Mar 1, 2010

DEERFIELD, Ill. and LONDON, U.K., March 1, 2010 – Baxter International Inc. (NYSE:BAX), a global, diversified healthcare company, and ApaTech, a private equity-backed, U.K.-based orthobiologic products company, today announced a definitive agreement whereby Baxter will acquire all of the outstanding equity of ApaTech for total consideration of up to $330 million. As a result of the acquisition, Baxter will acquire ACTIFUSE, a silicate substituted calcium phosphate synthetic bone graft material which is currently marketed in the United States, E.U., and other select markets around the world, and manufacturing and R&D facilities located in the U.K., United States and Germany.... Read More

Feb 16, 2010

DEERFIELD, Ill., February 16, 2010 – The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.29 per share of Baxter common stock.... Read More

Feb 4, 2010

Baxter International Inc. and The Baxter International Foundation have committed over $2.5 million to support disaster relief efforts in response to the devastating earthquake in Haiti.... Read More

Feb 3, 2010

Baxter International Inc. and The Baxter International Foundation have committed over $2.5 million to support disaster relief efforts in response to the devastating earthquake in Haiti.... Read More

Feb 1, 2010

The Global 100 list, announced each year during the World Economic Forum in Davos, Switzerland, includes the corporations that have been most proactive in managing environmental, social and governance issues. The list also acknowledges the companies with strong strategic management capabilities, capacity for innovation and ability to respond to changing competitive forces. View the Global 100 press release.... Read More

Jan 28, 2010

DEERFIELD, Ill., January 28, 2010 – Baxter International Inc. (NYSE:BAX) today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.... Read More

Jan 27, 2010

Baxter International Inc. (NYSE:BAX) today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.... Read More

Jan 14, 2010

CHICAGO, January 14, 2010 – In honor of its broad-based efforts to improve the lives of the most vulnerable members of its community, Heartland Health in St. Joseph, Mo., is the recipient of the prestigious 2009 Foster G. McGaw Prize for Excellence in Community Service, one of the most esteemed community service honors in healthcare.... Read More

Jan 14, 2010

Baxter International Inc. and The Baxter International Foundation have committed over $2.5 million to support disaster relief efforts in response to the devastating earthquake in Haiti.... Read More

Jan 14, 2010

Baxter International Inc. and The Baxter International Foundation have committed $1 million to support disaster relief efforts in response to the devastating earthquake in Haiti.  ... Read More

Jan 6, 2010

Deerfield, IL, January 6, 2010 – (BUSINESS WIRE) – Baxter International Inc. (NYSE: BAX) announced today that it will present at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 1:30 p.m. (PST) or 4:30 p.m. (EST).... Read More

Oct 31, 2005

Baxter International Inc. (NYSE:  BAX) announced today that it will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 28, 2012, at 2:05 p.m. (ET).... Read More